Immune-modulating effects of regular aerobic exercise in gastrointestinal disorders: Inflammatory markers and heart rate variability

Immune-modulating effects of regular aerobic exercise in gastrointestinal disorders: Inflammatory markers and heart rate variability | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Immune-modulating effects of regular aerobic exercise in gastrointestinal disorders: Inflammatory markers and heart rate variability Kelly A. Baker, Frank E. Marino, Tegan E. Hartmann This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-6348408/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract This study investigates the effects of a 12-week moderate-intensity aerobic exercise intervention on autonomic function, inflammatory markers, and symptom severity in those with gastrointestinal (GI) disorders, specifically inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), compared to apparently health controls (AHC). Heart rate variability (HRV) parameters, specifically low frequency, significant increased within the GI and AHC cohort post-intervention; additional increased parasympathetic parameters were observed in AHC. No significant reductions occurred in the inflammatory markers of CRP, TNF, or IL-17; although, a greater reduction in TNF concentration among AHC group resulted in a significant between-group difference post-intervention. Significant correlations indicated a negative correlation between TNF and parasympathetic HRV measures post-intervention. Twelve-weeks moderate-intensity aerobic exercise is effective to modulate autonomic function, particularly the autonomic balance, and provide a slight reduction in inflammatory cytokines among patients with GI disorders. The blunted vagal tone and dysregulated immunological-inflammatory profiles are speculated to hinder the physiological changes in IBD and IBS; although further research is required to support or refute this concept. This study supports use of exercise as a complementary intervention to maintain health, well-being, and physical fitness, without disease exacerbation or adverse effects of medication. Biological sciences/Immunology/Inflammation/Chronic inflammation Health sciences/Diseases/Gastrointestinal diseases Health sciences/Health care/Therapeutics Inflammatory bowel disease irritable bowel syndrome physical activity exercise autonomic regulation inflammatory response Figures Figure 1 Figure 2 Figure 3 Introduction The prevalence of gastrointestinal (GI) disorders, such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), is increasing [ 1 , 2 ]. IBD is primarily comprised of Crohn’s disease (CD) and ulcerative colitis (UC) [ 3 ]. This chronic idiopathic condition is characterised pathologically by intestinal inflammation which dominates the mucosa that destructs the structure and function of the GI tract [ 4 – 6 ]. In contrast, IBS is characterised by altered bowel habits associated with abdominal discomfort or pain [ 7 ]; however, low-grade inflammation, immunological alterations, and disruption of the gut-brain axis (GBA) are suggested to have important roles in the development of symptoms [ 8 – 11 ]. Erratic symptoms, such as altered bowel movements with either straining (IBS-constipation) or urgency/diarrhoea (IBS-diarrhoea or IBD), abdominal pain, and rectal bleeding, are predominantly present through the fluctuation of active disease states, where there is heighten inflammation or intensification of symptoms [ 12 – 15 ]. Such severe symptoms interfere with everyday activities, induce serious disability, provoke financial burden, and consequently, impact mental health and quality of life (QoL) [ 16 – 22 ]. Despite the variety of treatment options available, with varying success [ 23 – 29 ], the apparent need for an alternative and/or complementary therapeutic interventions for GI patients is acknowledged [ 24 , 30 – 32 ]. Physical activity is an established therapeutic intervention for the prevention and treatment of a variety of chronic conditions [ 33 ], the beneficial effects of physical activity have recently gained interest to further assist those with GI disorders. Physical activity is considered safe and effective for patients with GI disorders [ 34 – 38 ], with specific positive outcomes including improves QoL, well-being, and mental health among GI patients, as well as offers a protective role in the development of disease and advantageous effects on disease course [ 39 – 44 ]. Although, the underling mechanisms coordinating these positive outcomes are unknown, such changes may be attributed to the immune and inflammatory responses of exercise [ 45 – 48 ]. Studies that explore exercise among GI populations often rely on subjective measures of patients’ well-being and disease activity without objective markers of inflammation or investigation of the GBA, particularly, the autonomic nervous system (ANS) component. Such subjective measures are important to understand patients’ perception of exercise; however, greater exploration into the physiological mechanisms exercise modulates, such as immunological factors and autonomic aspects which contribute to the problematic symptomology, are essential to inform evidence-based exercise prescription within this population. Therefore, this study aims to investigate the immune-inflammatory responses and autonomic function to regular exercise in those with GI disorders. A secondary aim is to explore the symptomology and psychological impact of exercise. It is hypothesised people with GI disorders will observe a reduction in inflammatory markers with significant alterations in heart rate variability (HRV), specifically parameters that indicate a reduced sympathetic drive and increased parasympathetic stimulation. Additionally hypothesised, disease activity will remain stable with a reduction in anxiety and stress to occur. Results Participant Characteristics Table 1 displays all anthropometric and descriptive variables. The AHC group achieved significant improvements in VO2peak from pre- to mid- (p = .021) and post-intervention (p = .031), F(2, 24) = 6.889. No other significant changes were observed for the other variables throughout either group (p > .05). Due to a 3.2–4.7% reduction in the AHC group systolic BP from pre-values, a significant between-group difference was observed at mid- (p = .049) and post-intervention (p = .039). While based on the 7.9% reduction in the GI group diastolic BP from pre-values to post-values, there was no significant between-group differences at post-intervention (p > .05). Further, the 2.5% decline in waist-to-hip ratio in the AHC group between pre- and mid-intervention resulted in a significant group difference at mid- (p = .047) and post-intervention (p = .035). Moreover, significant difference between groups were observed at pre-, mid- and post-intervention for all body composition measures, including weight, body mass index (BMI), waist and hip circumference, percentage of fat mass, lean mass, and fat mass (kg; p < .05). No significant between- or within-factor difference for heart rate response and RPE throughout the training period, as shown in Fig. 1. All questionnaires and their respective results are present in Table 2. No significant within-groups changes were observed. WHO QoL scores were statistically significant between group across pre-, mid-, and post-intervention. Further, between-group significant differences were observed for anxiety scores pre- and mid-intervention; due to a 16% reduction in anxiety scores for the GI group from pre- to post-measure there was no significant difference post-intervention. Autonomic Function As displayed in Table 3, a significant between group interaction was identified in HRV measures of SD of normal-to-normal intervals (SDNN), F(1, 23) = 7.655, p = .011, root mean square of successive RR interval difference (RMSSD), F(1, 22) = 5.172, p = .033, high frequency (HF), F(1, 22) = 7.028, p = .015, and parasympathetic nervous system (PNS) index, F(1, 22) = 6.14, p = .021. Whereas significant pre- to post- differences were observed in AHC HF, F(2, 24) = 6.543, p = .007, LF, F(2, 24) = 7.284, p = .011, sympathetic nervous system (SNS) index, F(2, 24) = 4.334, p = .025, and PNS index, F(2, 24) = 4.619, p = .020, as well as GI low frequency (LF), F(2, 20) = 14.598, p = .002. No differences were observed in percentage of successive RR intervals (pNN50) or very low frequency (VLF). Table 3 Heart Rate Variability, Means and SD Pre-intervention Mid-intervention Post-intervention Measure GI ( n = 11) AHC ( n = 13) GI ( n = 11) AHC ( n = 13) GI ( n = 11) AHC ( n = 13) SDNN 39.57 ± 16.08 76.45 ± 38.66^ 53.61 ± 26.82 72.92 ± 41.86 42.48 ± 21.51 69.42 ± 44.61 RMSSD 29.94 ± 16.89 47.28 ± 38.39 40.87 ± 27.80 57.91 ± 42.23 33.03 ± 20.86 71.50 ± 52.57^ pNN50 11.48 ± 12.94 21.79 ± 19.27 19.04 ± 23.54 26.71 ± 24.39 12.98 ± 16.92 35.86 ± 26.32 HF 23.91 ± 12.52 19.84 ± 15.47 23.39 ± 16.46 25.15 ± 11.83 20.57 ± 16.42 40.11 ± 19.20*^ LF 41.41 ± 10.99 29.81 ± 15.88 42.24 ± 16.49 39.99 ± 23.50 65.65 ± 16.10* 52.21 ± 18.03* VLF 34.67 ± 15.93 50.32 ± 21.93 34.36 ± 23.98 36 ± 25.3 13.73 ± 9.18 7.65 ± 8.86 SNS Index 1.2 ± 1.12 0.49 ± 1.52 0.70 ± 2.05 0.32 ± 1.46 0.31 ± 1.55 -0.47 ± 1.01* PNS Index -0.65 ± 0.91 -0.77 ± 1.67 -0.18 ± 1.24 0.57 ± 1.32 -0.55 ± 1 1.13 ± 1.65*^ *Denotes significant difference compared to baseline ( p < .05) ^Denotes significant difference between the groups ( p < .05) Inflammatory Response Figure 2 represents the inflammatory response of CRP, TNF, and IL-17. Between-group differences were observed at pre- and mid-intervention for CRP (p = .040; p = .003), and post-intervention for TNF (p < .002). Further, between mid- and post-intervention TNF values for AHC were reported as significant different, F(1, 10) = 58.549, p = .015. No significant outcomes were observed for IL-17. Relationship Among Variables Several associations between variables were revealed through a Pearson’s correlation coefficient analysis. Table 4 displays the main study variables across the cohort at pre-, mid-, and post-intervention. Interestingly, post-intervention TNF concentrations were negatively associated with a variety of HRV parameters: SDNN, r(18) = − .460, p = .041, RMDSS, r(18) = − .524, p = .018, HF, r(18) = − .592, p = .006, and pNN50, r(18) = − .528, p = .006. Table 4 Pearson Correlations for Main Study Variables Pre-intervention 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 1. Fat mass 2. VO 2 peak -688** 3. Depression .412* − .214 4. Anxiety .389 − .135 .750** 5. Stress .523** − .168 .825** .811** 6. FAS .164 .232 .523** .563** .586** 7. WHO-QoL − .586** .139 − .687** − .599** − .693** − .603** 8. CRP .617** − .550** .565** .499* .582** .332 − .414* 9. TNF .344 − .233 .140 .143 − .045 − .099 − .373 .199 10. SDNN − .460* .547** − .250 − .233 − .251 − .048 .217 − .307 − .102 11. RMDSS − .355 .348 − .222 − .222 − .215 − .069 .219 − .244 − .101 .912** 12. HF .114 − .148 .006 .006 .038 .038 .030 − .106 − .207 .166 .482* 13. pNN50 − .280 .275 − .233 − .233 − .140 − .084 .242 − .300 − .144 .803** .942** .602** Mid-intervention 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 1. Fat mass 2. VO 2 peak − .749** 3. Depression .250 − .187 4. Anxiety .448* − .244 .489* 5. Stress .312 − .213 .820** .751** 6. FAS .188 .001 .817** .342 .677** 7. WHO-QoL − .627** .292 − .639** − .551** − .625** − .688** 8. CRP .469* − .570** .236 .073 .169 .252 − .391 9. TNF .512* − .327 .306 .181 .236 .511 − .599** .527* 10. SDNN − .148 .379 − .276 − .181 − .358 − .028 .066 − .235 − .322 11. RMDSS − .052 .227 − .181 − .120 − .266 − .049 .057 − .176 − .377 .928** 12. HF .023 .056 .152 .047 .069 − .030 .059 − .111 − .352 .316 .577** 13. pNN50 − .032 .229 − .149 − .180 − .242 .014 .039 − .110 − .329 .851** .928** .624** Post-intervention 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 1. Fat mass 2. VO 2 peak − .799* 3. Depression .238 − .026 4. Anxiety .239 − .098 .774** 5. Stress .163 − .012 .902** .787** 6. FAS .090 .095 .776** .605** .735** 7. WHO-QoL − .529** .216 − .685** − .684** − .604** − .556** 8. CRP .310 − .339 .317 .351 .173 .229 − .381 9. TNF .218 − .238 − .002 − .039 − .036 − .061 − .201 − .041 10. SDNN − .163 .230 − .163 − .227 − .051 .161 .160 − .137 − .460* 11. RMDSS − .174 .228 − .138 − .233 -0.11 .157 .215 − .201 − .524* .960** 12. HF − .211 .272 − .081 − .266 .041 .113 .329 − .263 − .592* .446* .621** 13. pNN50 − .117 .247 − .163 − .260 .009 .101 .292 − .188 − .528* .859** .922** .736** Note. CRP, C-reactive protein: FAS, fatigue assessment questionnaire: HF, high frequency: pNN50, percentage of successive RR intervals: RMDSS, root mean square of successive RR interval differences: SDNN, standard deviation of N-N (normal-to-normal) intervals: TNF, tumor necrosis factor: VO 2 peak , peak oxygen consumption: WHO-QoL, World Health Organisation Quality of Life. * p < .05: ** p < .01 Discussion The purpose of this study was to investigate the immune-inflammatory responses of CRP, TNF, and IL-17, and evaluate autonomic function following 12-weeks of aerobic exercise training. Accordingly, the novel finding of this study revealed HRV parameters, specifically LF, significantly increased within the GI and AHC group post-intervention. Interestingly, among the AHC group significant changes that indicate a reduction in sympathetic drive and increased parasympathetic stimulation were observed post-intervention; therefore, these findings were partially consistent with the hypothesis as significant alterations occurred in HRV parameters. Although, in contrast to the research hypothesis, no significant within-group reduction in CRP, TNF, or IL-17 were observed. A non-significant reduction in CRP concentrations within the GI group resulted in no between-group differences post-intervention, whereas a decline in TNF within the AHC group resulted in between-group differences post-intervention. Additionally, a moderate negative correlation between TNF and parasympathetic HRV measures were observed. Collectively, these findings support the beneficial effects of exercise and safety for the prescription of exercise as a therapeutic intervention to assist with management. Further, due to the pathophysiology of IBD and IBS, people with those disorders may require longer periods of training to achieve similar advantageous effects to the AHC group, specifically for autonomic function and immune-inflammatory responses. A greater exploration of the underlying physiological mechanisms associated with GI disorders in response to other exercise modalities is required to draw conclusive results. Autonomic Function to Training Immunity, inflammation, and motility of the GI tract is regulated by the ANS, specifically the interaction of the parasympathetic and sympathetic nervous systems [ 49 , 50 ]. Evidence suggests autonomic dysfunctions occurs in patients with GI disorders, such as IBD and IBS [ 51 – 53 ]. Accordingly, these results support this notion as SDNN, a time-domain HRV measure that reflects parasympathetic activity [ 54 ], is significant lower pre-intervention in the GI group compared to AHC; therefore, a reduction of SDNN indicates higher sympathetic response and reduced parasympathetic activity. The restoration of ANS is an important variable in the development and monitoring of therapeutic interventions for GI patients [ 55 , 56 ]. Exercise exerts favourable effects on HRV that may improve autonomic modulation, through an increase of vagal activity and decrease sympathetic tone [ 57 – 61 ]. As such, significant within-group increases were observed for LF, a frequency-domain parameter that is influenced by both sympathetic and parasympathetic activity [ 54 ], from pre- to post-exercise intervention among the GI and AHC group. The predominant evaluation of parasympathetic activity is further observed in the AHC cohort, as additional within-group significant changes post-intervention were revealed including an increase in HF and PNS index, and a decrease in SNS index. While our findings support the use of physical activity to induce autonomic modulation for GI and AHC cohorts, the blunted vagal tone distinguished in IBD and IBS may hinder adaptations to the ANS [ 62 – 64 ]. Inflammatory Response to Training Regular exercise promotes a reduction in low-grade systemic inflammation through the inhibitory effect on pro-inflammatory cytokine production derived from acute bouts of exercise [ 65 , 66 ]. This is identified in a variety of studies with various clinical and non-clinical cohorts [ 67 – 71 ]. Despite an observed reduction in CRP among the GI group, our findings did not achieve within-group statistical significance for either cohort. Additionally, the greater decline of TNF within the AHC group resulted in between-group significance differences post-intervention. While there is minimal evidence regarding this process among those GI patients [ 34 , 72 ], no notable effects may be explained with two reasons: (1) the immunological-inflammatory alterations involved in GI patients [ 5 , 9 , 10 ] may hinder the immune-modulating effects of exercise and require a longer exercise intervention to stimulus change, and (2) due to the medication use among the GI cohort. As medication is designed to suppress intestinal inflammation [ 73 ], the exercise-induced immune-modulating effect may be inhibited. More specifically, the half-life of medication varies from hours to weeks depending on the medication and dose [ 74 – 76 ]; therefore, the timing between medication and the exercise stimulus requires investigation to potentially elicit the advantageous immune-inflammatory adaptations. Furthermore, as no influx of pro-inflammatory markers occurred or increase in disease activity questionnaire, this study supports the safety of moderate-intensity aerobic exercise among patients with IBD and IBS. Relationship Amongst Autonomic Function and Inflammatory Response to Training Despite the minimal significant changes among HRV and inflammatory response, this study observed a significant negative correlation between TNF concentrations and a variety of parasympathetic HRV measures post-intervention. This association that indicates an increase of parasympathetic HRV parameters is related to a decrease in inflammatory TNF is anticipated, given the physiological relationship of the PNS, through the vagus nerve, and inflammatory processes [ 50 ]. The vagus nerve is recognised as the primary connection between local inflammation and central nervous system (CNS) activity [ 50 ]. More specifically, the production of pro-inflammatory cytokines, such as TNF, is modulated through vagal efferent activation of the cholinergic anti-inflammatory pathway and the afferent regulation of the HPA axis [ 77 – 79 ]. In theory, activating the vagus nerve will stimulate the anti-inflammatory properties, reduce abnormal inflammation, and balance the dysregulated ANS. Although, due to limited evidence, Sadowski, Dunlap [ 80 ] recommends the associated HRV parameters with GI pathology remains speculative. While the underlying physiological mechanisms that influence ANS and vagus tone in people with GI disorders warrant further investigation, our findings highlight a noteworthy outcome that aerobic exercise can influence HRV parameters and further results in a decline of inflammatory markers. To strengthen these findings, exploration of exercise modalities in relation to inflammation and HRV is required. Limitations Initially, AHC were intended to be ‘matched’ with the GI cohort for body composition; however, as recruitment transpired, the two cohorts were not matched with several body composition measures and were identified to be significantly different between the groups. Given that pro- and anti-inflammatory factors are produced and released in adipose tissue [ 81 ], future research should attempt to recruitment ‘healthy matched controls’ to regulate this variable. Additionally, participants were instructed to abstain from caffeine, alcohol, and strenuous physical activity prior to all testing session, and continue everyday life activities throughout the intervention; although, conformity was difficult to manage and entrusted with the individual. Finally, medication usage of participants was not strictly monitored during this study. Conclusion In conclusion, the findings from the present study suggest 12-weeks of moderate intensity aerobic exercise is effective to modulate autonomic function, specifically autonomic balance, and provide a slight reduction to inflammatory cytokines that could be biologically relevant among those with GI disorders. Moreover, it is speculated that the blunted vagal tone, dysregulated inflammatory profiles, and medication use associated with GI disorders may dampen the velocity of change. These results support the use of physical activity as a therapeutic intervention, in combination with other management strategies, including medication, to maintain health, well-being and physical fitness. To further inform health professionals with favourable exercise interventions, the amelioration of ANS, activation of the vagus nerve, and mitigation of immune-inflammatory response of different exercise modalities requires investigation. Methods Participants Twenty-six participants were initially recruited, and 24 participants completed the study by participating in the 12-week exercise intervention (female: n = 16, male: n = 8), yielding a total drop-out rate of 8%. All participants were recruited from the general community and allocated into one of two groups: GI group (IBD, n = 6; IBS, n = 5; total n = 11) or reporting as apparently healthy controls (AHC; n = 13). All participants were between 18 and 63 years of age, Caucasian and were non-smokers. A variety of comorbid conditions were present in the GI group (depression, n = 2; type 2 diabetes, n = 1; fibromyalgia and chronic fatigue, n = 1). For participants in the GI group receiving medication as treatment (n = 5/11), a stable dose was required; however, due to the nature of disease, medication varied throughout the intervention. In total, 8 of 11 GI participants were receiving medications (specific IBD medication, n = 5; anti-depressants, n = 2; and thyroid medication, n = 1). AHC had no known illness, disease, or condition, and were free from any form of cancer, diabetes, cardiovascular disease, epilepsy, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, or other neuromotor disorders, and any other diseases or conditions associated with systemic inflammatory responses. Participants were not excluded based on inflammatory biomarkers, disease activity, medication use, or physical activity behaviours. Ethics Declaration Prior to commencement of the study, all participants were required to provide verbal and written consent following an outline of all procedures and measures. Informed consent was obtained from all participants. This study conformed to the Declaration of Helsinki and was approved by the Human Research Ethics Committee (protocol number: H22224), Biosafety Committee (protocol number: B22003HB), and Radiation Safety Committee (protocol number: R22003RP) at Charles Sturt University. Study Overview Prior to enrolment, IBD participants were required to undergo medical screening by their general practitioner (GP) for confirmation of diagnosis and admittance into the study; IBS participants were screened for eligibility according to the Rome IV criteria [ 82 ]. All participants had their health characteristics assessed through a health history questionnaire and an Adult Pre-Exercise Screening System (APSS). Participants then reported to the laboratory between 0500hr and 0900hr rested and fasted (10hr overnight fast) for an initial baseline testing that included a blood sample, measures of anthropometry, dual-energy x-ray absorptiometry (DEXA) scan, and a graded exercise test (GXT). Following baseline testing, all participants began the 12-week aerobic training intervention, 3 sessions/week. Additional testing sessions, comprising of the same pre-test procedures, were completed at 6-weeks (mid-intervention) and 12-weeks (post-intervention). An overview is displayed in Fig. 3. Exercise Intervention Progression Testing Sessions Following recruitment, participants attended a pre-testing session between 0500hr and 0900hr in a rested and fasted state (10hr overnight fast). All participants completed a Fatigue Assessment Questionnaire (FAS), Depression, Anxiety, and Stress Scales (DASS)-21, and the World Health Organisation Quality of Life (WHO QoL)-BREF. Additional disease-specific questionnaires were used to assess disease severity for the GI group: Harvey-Bradshaw Index (HBI), the Simple Clinical Colitis Activity Index (SCCAI), or the IBS-Symptom Severity Scale (IBS-SSS) for CD, UC, and IBS, respectively. Then a blood sample was collected (subsequently described), followed by the collection of anthropometry assessments based on standardised techniques: stature (Stadiometer: Custom CSU, Bathurst, Australia), body mass (HW 150 K, A & D, Bradford, MA, USA), waist and hip girths (Steel tape, EC P3 metric graduation, Sydney, NSW, Australia), resting blood pressure (BP; Welch Allyn, Arden, North Carolina, USA), heart rate (HR; Rs800cx, Vantage NV, Polar, Finland), and a 5min heart rate variability (HRV) recording (Polar Team Pro, Polar Electro Oy, Kempele, Finland). Participants then underwent a DEXA scan to determine body fat percentage, total fat mass, and lean mass (GE Lunar Prodigy, GE Healthcare, Madison, WI, USA). Lastly, participants performed a GXT on an electronically braked cycle ergometer (LODE Excalibur Sport, LODE BV, Groningen, The Netherlands) for the determination of peak oxygen consumption (VO2peak); expired gases were analysed by a calibrated metabolic cart (TrueOne 2400, ParvoMedics, Salt Lake City, Utah). The GXT increased 25 Watts (W) per minute until volitional exhaustion and commenced at either 25 W or 100 W. Every minute, rated of perceived exertion (RPE) and HR was recorded. Upon completion of 6-weeks and 12-weeks of the intervention, all participants returned to the laboratory for mid-testing and post-testing procedures, respectively, that comprised of the same standardised pre-testing session. Exercise Intervention Following the pre-testing session, all participants began the 12-week aerobic exercise training intervention that consisted of a continuous stationary cycle ergometry (Monark 828E, Monark Exercise AB, Varburg, Sweden). Training intensity or duration increased in 3-week blocks, as shown in Fig. 1: week 1–3, 65% of heart rate reserve (HRR) for 35min; week 4–6, 65% of HRR for 40min; week 7–9, 70% of HRR for 40min; and week 10–12, 70% of HRR for 45min (three supervised sessions per week). Every 5min RPE (Borg 0–10) [ 83 ] and HR (Vantage NV, Polar, Kempele, Finland) were recorded to ensure training intensity was safely adhered to. All sessions were supervised by a member of the research team with a 24-48hr recovery period interspersed between each session. Participants were instructed to continue normal lifestyle behaviour outside the parameters of the study. Biomarker Quantification Venous blood was collected to determine inflammatory markers pre-, mid- and post-intervention via a 21-gauge winged butterfly needle into the medical antecubital vein. Approximately 25ml of blood was manually drawn by syringe, ejected, and aliquoted into ethylenediaminetetraacetic acid (EDTA) tubes and a serum-separating tube (SST) for analysis of C-reactive protein (CRP), tumor necrosis factor (TNF), and interleukin (IL)-17. EDTA tubes were centrifuged immediately at 3500 rpm for 15min at 4⁰C; SST were left to clot for approximately 30min then centrifuged at 3500 rpm for 15min. Supernatants were immediately stored at -80⁰C until analysis. Samples were analysed in duplicate with a sandwich enzyme immunoassay technique (Thermo Scientific Multiskan FC), according to manufacturer’s instructions and analytical techniques: CRP at a 25 000 fold dilution (C Reactive Protein Human ELISA Kit, catalog number 1063321-1, abcam, Cambridge, United Kingdom), TNF at a 1:2 fold dilution (Human TNF alpha SimpleStep ELISA Kit, catalog number 2101050759, abcam, Cambridge, United Kingdom), and IL-17 high sensitively (HS; Human IL-17 Immunoassay, catalog number HS170). Intra-assay and inter-assay coefficients of variation were < 10% and < 12% for CRP, 2.5% and 3.1% for TNF, and 3.5% and 6.9% for IL-17HS, respectively. Statistical Analysis Mean ± standard deviation (SD) was used to report all anthropometric, descriptive and questionnaire data. A two-way mixed analysis of variance (ANOVA; group x time) with a Bonferroni correction was applied to determine main and interaction effects. The assumption of normality was assessed by the Shapiro-Wilk W test with violations reported or log transformation applied. The assumption of homogeneity of variances was assessed by Levene’s Test of Equality of Error Variances and Box’s Test of Equality of Covariance Matrices with violations reported. Mauchly’s Test of Sphericity was applied for within-subject effects. To determine a significant difference between pre-, mid-, and post- characteristics and performance measures, a one-way repeated ANOVA was used with a one-way ANOVA used for between group differences. To determine relationships among variables, Pearson’s Correlation Coefficients were used. Significance was set at p < .05. All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS; IMB SPSS Statistics for Windows, Version 27.0. Armonk, NY). A priori power analysis was completed using G*Power (G*Power v3.1.9.6). For statistical power of 0.80, the output parameters determined a sample size of 28 was required. However, this study had a power of 0.70 with a sample size of 24. While the sample size and power are reflective of the availability of research participants in regional and rural Australia, we recognise the potential limitation of reduced power. Nevertheless, even with marginally reduced statistical power, the study provides a unique snapshot of the effects of exercise training in this group. Declarations Acknowledgements The authors would like to thank the participants for participating in this 12-week training study. The authors would like to acknowledge the Charles Sturt University open access publishing grant. Author contributions Kelly A. Baker : Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Resources; Validation; Writing – original draft; Writing – review & editing. Frank E. Marino : Conceptualization; Investigation; Methodology; Supervision; Validation; Writing – review & editing. Tegan E. Hartmann : Conceptualization; Investigation; Methodology; Supervision; Validation; Writing – review & editing. Data availability statement Data can be made available upon reasonable request to the corresponding author. Competing Interests Statement The authors declare that no completing interests exist. References Alatab, S., et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology & Hepatology . 5 (1), 17-30; 10.1016/S2468-1253(19)30333-4 (2020). Black, C.J. and Ford, A.C. Global burden of irritable bowel syndrome: Trends, predictions and risk factors. Nature Reviews Gastroenterology & Hepatology , 2020. 17 (8), 473-486; 10.1038/s41575-020-0286-8 (2020). Sands, B.E. From symptom to diagnosis: Clinical distinctions among various forms of intestinal inflammation. Gastroenterology . 126 (6), 1518-1532; 10.1053/j.gastro.2004.02.072 (2004). Coskun, M. Intestinal epithelium in inflammatory bowel disease. Frontiers in Medicine . 1 , 24; 10.3389/fmed.2014.00024 (2014). Neurath, M.F. Cytokines in inflammatory bowel disease. Nature Reviews Immunology . 14 (5), 329-342; 10.1038/nri3661 (2014). Okamoto, R. and Watanabe, M. Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. Journal of Gastroenterology . 51 (1), 11-21; 10.1007/s00535-015-1098-4 (2016). Drossman, D.A. and Dumitrascu, D.L.Rome III: New standard for functional gastrointestinal disorders. Journal of Gastrointestinal and Liver Diseases: JGLD . 15 (3), 237-241; (2006). Fichna, J. and Storr, M.A. Brain-gut interactions in IBS. Frontiers in Pharmacology . 3 , 127; 10.3389/fphar.2012.00127 (2012). Ng, Q.X., Soh, A.Y.S., Loke,W., Lim, D.Y., & Yeo, W.S. The role of inflammation in irritable bowel syndrome (IBS). Journal of Inflammation Research . 345-349; 10.2147/JIR.S174982 (2018). Öhman, L. and Simrén, M. Pathogenesis of IBS: Role of inflammation, immunity and neuroimmune interactions. Nature Reviews Gastroenterology & Hepatology . 7 (3), 163-173; 10.1038/nrgastro.2010.4 (2010). Videlock, E.J. and Chang, L. Latest insights on the pathogenesis of irritable bowel syndrome. Gastroenterology Clinics . 50 (3), 505-522; 10.1016/j.gtc.2021.04.002 (2021). Perler, B.K., et al., Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort. BMC Gastroenterology . 19 (1), 1-8; 10.1186/s12876-019-0963-7 (2019). Peyrin-Biroulet, L., Loftus, E.V., Colombel, J.F., & Sandborn, W.J. Defining disease severity in inflammatory bowel diseases: Current and future directions. Clinical Gastroenterology and Hepatology . 14 (3), 348-354, e17; 10.1002/ibd.21417 (2016). Shah, E.D., Almario, C.V., Spiegel, B.M., & Chey, W.D. Presentation and characteristics of abdominal pain vary by irritable bowel syndrome subtype: Results of a nationwide population-based study. The American Journal of Gastroenterology . 115 (2), 294; 10.14309/ajg.0000000000000502 (2020). Soares, R.L., Irritable bowel syndrome: A clinical review. World Journal of Gastroenterology: WJG . 20 (34), 12144-12160; 10.3748%2Fwjg.v20.i34.12144 (2014). Barberio, B., Zamani, M., Black, C.J., Savarino, E.V., & Ford, A.C. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: A systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology . 6 (5), 359-370; 10.1016/S2468-1253(21)00014-5 (2021). Häuser, W., Layer, P., Henningsen, P., & Kruis, W. Functional bowel disorders in adults. Deutsches Ärzteblatt International . 109 (5), 83; 10.3238%2Farztebl.2012.0083 (2012). Jones, J.L., et al. The impact of inflammatory bowel disease in Canada 2018: Quality of life. Journal of the Canadian Association of Gastroenterology . 2 (Supplement_1), S42-S48; 10.1093/jcag/gwy048 (2019). Liang, A.M. and Y. Tien, Quality of life in irritable bowel syndrome: A narrative overview. Journal of Archives in Military Medicine . 4 (1); 10.5812/jamm.36624 (2016). Mikocka‐Walus, A., et al. Psychological comorbidity and complexity of gastrointestinal symptoms in clinically diagnosed irritable bowel syndrome patients. Journal of Gastroenterology and Hepatology . 23 (7pt1), 1137-1143; 10.1111/j.1440-1746.2007.05245.x (2008). Zamani, M., Alizadeh‐Tabari, S. and Zamani, V. Systematic review with meta‐analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. Alimentary Pharmacology & Therapeutics . 50 (2), 132-143; 10.1111/apt.15325 (2019). Baker, K.A., Marino, F.E. and Hartmann, T.E. Living with inflammatory bowel disease in Australia: Quality of life and the impact of support networks. Therapeutic Advances in Gastroenterology . 17 ; 10.1177/17562848241264362 (2024). Bertani, L., et al. Fecal calprotectin predicts mucosal healing in patients with ulcerative colitis treated with biological therapies: A prospective study. Clinical and Translational Gastroenterology . 11 (5); 10.14309/ctg.0000000000000174 (2020). Chudy-Onwugaje, K.O., Christian, K. E. Farraye, F. A. & Cross, R. K. A state-of-the-art review of new and emerging therapies for the treatment of IBD. Inflammatory Bowel Diseases . 25 (5), 820-830; 10.1093/ibd/izy327 (2019). Duff, W., et al. Non-pharmacological therapies for inflammatory bowel disease: Recommendations for self-care and physician guidance. World Journal of Gastroenterology . 24 (28), 3055-3070; 10.3748%2Fwjg.v24.i28.3055 (2018). Im, J.P., et al. Changing treatment paradigms for the management of inflammatory bowel disease. The Korean Journal of Internal Medicine . 33 (1), 28; 10.3904%2Fkjim.2017.400 (2018). Ko, Y. and Ho, V. Irritable bowel syndrome an update on diagnosis and management. Medicine Today . 22 (8); (2021). Shorey, S., Demutska, A. Chan, V. & Siah, K.T.H. Adults living with irritable bowel syndrome (IBS): A qualitative systematic review. Journal of Psychosomatic Research . 140 , 110289; 10.1016/j.jpsychores.2020.110289 (2021). van Linschoten, R.C.A., et al. Systematic review: Societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Alimentary Pharmacology & Therapeutics . 54 (3), 234-248; 10.1111/apt.16445 (2021). Amsallem, F., Sanchez, S. Armoiry, X. & Mion, F. Effectiveness of non-pharmacological interventions for irritable bowel syndrome: A systematic review. Evidence-Based Complementary and Alternative Medicine . 2021 (1); 10.1155/2021/4404185 (2021). Bilski, J., et al. Can exercise affect the course of inflammatory bowel disease? Experimental and clinical evidence. Pharmacological Reports . 68 (4), 827-836; 10.1016/j.pharep.2016.04.009 (2016). Yoon, S.L., Grundmann, O. Koepp, L. & Farrell, L. Management of irritable bowel syndrome (IBS) in adults: Conventional and complementary/alternative approaches. Alternative Medicine Review . 16 (2), 134-151; (2011). Thompson, W.R., et al. Exercise is medicine. American Journal of Lifestyle Medicine . 14 (5), 511-523; 10.1177/1559827620912192 (2020). Baker, K.A., Miller, T.D. Marino, F.E. & Hartmann, T.E. The exercise-induced inflammatory response in inflammatory bowel disease: A systematic review and meta-analysis. PloS One . 17 (2), e0262534; 10.1371/journal.pone.0262534 (2022). Cronin, O., et al., Moderate-intensity aerobic and resistance exercise is safe and favorably influences body composition in patients with quiescent Inflammatory Bowel Disease: A randomized controlled cross-over trial. BMC Gastroenterology . 19 (1), 1-11; 10.1186/s12876-019-0952-x (2019). Klare, P., et al. The impact of a ten-week physical exercise program on health-related quality of life in patients with inflammatory bowel disease: A prospective randomized controlled trial. Digestion . 91 (3), 239-247; 10.1159/000371795 (2015). Radziszewska, M., Smarkusz-Zarzecka, J. and Ostrowska, L. Nutrition, physical activity and supplementation in irritable bowel syndrome. Nutrients . 15 (16); 10.3390/nu15163662 (2023). Rey, E., The role of physical exercise in the treatment of IBS. Neuro Gastro Latem Reviews , 3 (2), 92-104; 10.24875/NGL.19000033 (2019). Davis, S.P., Crane, P.B. Bolin, L.P. & Johnson, L.A. An integrative review of physical activity in adults with inflammatory bowel disease. Intestinal Research . 20 (1), 43-52; 10.5217/ir.2020.00049 (2021). Gao, X., Tian, S. Huang, N. Sun, G. & Huang, T. Associations of daily sedentary behavior, physical activity, and sleep with irritable bowel syndrome: A prospective analysis of 362, 193 participants. Journal of Sport and Health Science . 10.1016/j.jshs.2023.02.002 (2023). Holik, D., et al. The effect of daily physical activity on the activity of inflammatory bowel diseases in therapy-free patients. Acta Clinica Croatica . 58 (2), 202-211; 10.20471/acc.2019.58.02.02 (2019). Johannesson, E., Ringström, G. Abrahamsson, H. & Sadik, R. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. World Journal of Gastroenterology: WJG . 21 (2), 600-608; 10.3748%2Fwjg.v21.i2.600 (2015). Lamers, C.R., de Roos, N.M. Koppelman, L.J. Hopman, M.T. & Witteman, B. J. Patient experiences with the role of physical activity in inflammatory bowel disease: Results from a survey and interviews. BMC Gastroenterology . 21 (1), 1-9; 10.1186/s12876-021-01739-z (2021). Madva, E.N., et al. Positive psychological well‐being: A novel concept for improving symptoms, quality of life, and health behaviors in irritable bowel syndrome. Neurogastroenterology & Motility . 35 (4), e14531; 10.1111/nmo.14531 (2023). Bruunsgaard, H. Physical activity and modulation of systemic low‐level inflammation. Journal of Leukocyte Biology . 78 (4), 819-835; 10.1189/jlb.0505247 (2005). Moldoveanu, A.I., Shephard, R.J. and Shek, P.N. The cytokine response to physical activity and training. Sports Medicine . 31 (2), 115-144; 10.2165/00007256-200131020-00004 (2001). Ortega, E. The “bioregulatory effect of exercise” on the innate/inflammatory responses. Journal of Physiology and Biochemistry . 72 (2), 361-369; 10.1007/s13105-016-0478-4 (2016). Zaldivar, F., et al. Constitutive pro-and anti-inflammatory cytokine and growth factor response to exercise in leukocytes. Journal of Applied Physiology . 100 (4), 1124-1133; 10.1152/japplphysiol.00562.2005 (2006). Kim, K.-N., Yao, Y. and Ju, S.-Y. Heart rate variability and inflammatory bowel disease in humans: A systematic review and meta-analysis. Medicine . 99 (48). 10.1097/MD.0000000000023430 (2020). Williams, D.P., et al. Heart rate variability and inflammation: A meta-analysis of human studies. Brain, Behavior, and Immunity . 80 , 219-226; 10.1016/j.bbi.2019.03.009 (2019). Engel, T., Ben-Horin, S. and Beer-Gabel, M. Autonomic dysfunction correlates with clinical and inflammatory activity in patients with Crohn's disease. Inflammatory Bowel Diseases . 21 (10), 2320-2326; 10.1097/MIB.0000000000000508 (2015). Sharma, P., Makharia, G.K. Ahuja, V. Dwivedi, S.N. & Deepak, K.K. Autonomic dysfunctions in patients with inflammatory bowel disease in clinical remission. Digestive Diseases and Sciences . 54 , 853-861; 10.1007/s10620-008-0424-6 (2009). Yildirim, A., et al. Is there any association between irritable bowel syndrome subgroups and autonomous dysfunction. European Review for Medical & Pharmacological Sciences . 20 (7); (2016). Ali, M.K. and Chen, J.D. Roles of Heart Rate Variability in Assessing Autonomic Nervous System in Functional Gastrointestinal Disorders: A Systematic Review. Diagnostics . 13 (2), 293; 10.3390/diagnostics13020293 (2023). Mogilevski, T., Burgell, R. Aziz, Q. & Gibson, P.R. the role of the autonomic nervous system in the pathogenesis and therapy of IBD. Alimentary Pharmacology & Therapeutics , 2019. 50 (7), 720-737; 10.1111/apt.15433 (2019). Salvioli, B., et al. Autonomic nervous system dysregulation in irritable bowel syndrome. Neurogastroenterology & Motility . 27 (3), 423-430; 10.1111/nmo.12512 (2015). Amano, M., Kanda, T. Ue, H. & Moritani, T. Exercise training and autonomic nervous system activity in obese individuals. Medicine & Science in Sports & Exercise . 33 (8), 1287-1291; (2001). Collins, B.E., et al. Moderate continuous-and high-intensity interval training elicit comparable cardiovascular effect among middle-aged men regardless of recovery mode. European Journal of Sport Science . 23 (8),1-10; (2023). Nagai, N., Hamada, T. Kimura, T. & Moritani, T. Moderate physical exercise increases cardiac autonomic nervous system activity in children with low heart rate variability. Child's Nervous System . 20 , 209-214; 10.1007/s00381-004-0915-5 (2004). Picard, M., et al. Effect of exercise training on heart rate variability in type 2 diabetes mellitus patients: A systematic review and meta-analysis. PLoS One , 2021. 16 (5), e0251863; 10.1371/journal.pone.0251863 (2021). Routledge, F.S., Campbell, T.S. McFetridge-Durdle, J.A. & Bacon, S.L. Improvements in heart rate variability with exercise therapy. Canadian Journal of Cardiology . 26 (6), 303-312; 10.1016/S0828-282X(10)70395-0 (2010). Bonaz, B., Sinniger, V. and Pellissier, S. The vagus nerve in the neuro-immune axis: implications in the pathology of the gastrointestinal tract. Frontiers in Immunology . 8 , 1452; 10.3389/fimmu.2017.01452 (2017). Bonaz, B.L. and Bernstein, C.N. Brain-gut interactions in inflammatory bowel disease. Gastroenterology . 144 (1), 36-49; 10.1053/j.gastro.2012.10.003 (2013). Pellissier, S., Dantzer, C. Canini, F. Mathieu, N. & Bonaz, B. Psychological adjustment and autonomic disturbances in inflammatory bowel diseases and irritable bowel syndrome. Psychoneuroendocrinology . 35 (5), 653-662. 10.1016/j.psyneuen.2009.10.004 (2010). Beavers, K.M., Brinkley, T.E. and Nicklas, B.J. Effect of exercise training on chronic inflammation. Clinica Chimica Acta . 411 (11-12), 785-793. 10.1016/j.cca.2010.02.069 (2010). Petersen, A. and Pedersen, B. The role of IL-6 in mediating the anti inflammatory. J Physiol Pharmacol . 57 (Suppl 10), 43-51; (2006). Ambarish, V., Chandrashekara, S. and Suresh, K. Moderate regular exercises reduce inflammatory response for physical stress. Indian J Physiol Pharmacol . 56 (1), 7-14; (2012). Campbell, P.T., et al. A yearlong exercise intervention decreases CRP among obese postmenopausal women. Medicine and Science in Sports and Exercise . 41 (8); 10.1249%2FMSS.0b013e31819c7feb (2009). Goldhammer, E., et al. Exercise training modulates cytokines activity in coronary heart disease patients. International Journal of Cardiology . 100 (1), 93-99; 10.1016/j.ijcard.2004.08.073 (2005). Metsios, G.S., Moe, R.H. and Kitas, G.D. Exercise and inflammation . Best Practice & Research Clinical Rheumatology . 32 (2), 101504; 10.1016/j.berh.2020.101504 (2020). Stewart, L.K., et al. The influence of exercise training on inflammatory cytokines and C-reactive protein. Medicine and Science in Sports and Exercise . 39 (10), 1714; 10.1249/mss.0b013e31811ece1c (2007). Ahmad, M.N. and Thnaibat, O.M. Can physical exercise help people with irritable bowel syndrome? How substantial is the evidence? Health, Sport, Rehabilitation . 9 (4), 94-110; 10.58962/HSR.2023.9.4.94-110 (2023). Neurath, M.F. Current and emerging therapeutic targets for IBD. Nature Reviews Gastroenterology & Hepatology . 14 (5), 269-278; 10.1038/nrgastro.2016.208 (2017). Moreno, L.O., Fernández-Tomé, S. and Abalo, R. Biological treatments in inflammatory bowel disease: a complex mix of mechanisms and actions. Biologics . 1 (2), 189-210; 10.3390/biologics1020012 (2021). Papamichael, K., et al. Infliximab in inflammatory bowel disease. Therapeutic Advances in Chronic Disease . 10 , 2040622319838443; 10.1177/2040622319838443 (2019). Wiersma, H., et al. Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease. Inflammatory Bowel Diseases . 10 (5), 626-631; 10.1053/j.gastro.2018.02.014 (2004). Bonaz, B., Sinniger, V. and Pellissier, S. Anti‐inflammatory properties of the vagus nerve: potential therapeutic implications of vagus nerve stimulation. The Journal of Physiology . 594 (20), 5781-5790; 10.1113/JP271539 (2016). Pavlov, V.A., et al. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain, Behavior, and Immunity . 23 (1), 41-45; 10.1016/j.bbi.2008.06.011 (2009). Pellissier, S., et al. Relationship between vagal tone, cortisol, TNF-alpha, epinephrine and negative affects in Crohn’s disease and irritable bowel syndrome. PloS One . 9 (9), e105328; 10.1371/journal.pone.0105328 (2014). Sadowski, A., Dunlap, C. Lacombe, A. & Hanes, D. Alterations in heart rate variability associated with irritable bowel syndrome or inflammatory bowel disease: A systematic review and meta-analysis. Clinical and Translational Gastroenterology . 12 (1); 10.14309/ctg.0000000000000275 (2021). Fantuzzi, G. Adipose tissue, adipokines, and inflammation. Journal of Allergy and Clinical Immunology . 115 (5), 911-919; 10.1016/j.jaci.2005.02.023 (2005). Drossman, D.A. and Tack, J. Rome Foundation clinical diagnostic criteria for disorders of gut-brain interaction. Gastroenterology , 2022. 162 (3), 675-679; 10.1053/j.gastro.2021.11.019 (2022). Borg, G. Borg's perceived exertion and pain scales. (Human kinetics, 1998). Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-6348408","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":444955885,"identity":"356f4f9f-3463-4461-b457-19458402bb6e","order_by":0,"name":"Kelly A. Baker","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAyElEQVRIiWNgGAWjYBACCQkGZiBlA+HxkKAljXQth0nQIjm7+bHBxz3n5eVnJDA+eNvGIG9wgIAWaZljxokznt023HAjgdlwbhuD4QZCWuQkEowP8xy4nWAgkcAmzdvGwEiElvTPh/8cOJcAdBj7b6AWe4JapCVyjJMZDhxIYLiRwMYM1JJIUIvknDPFhj0Hkg03nHnYLDnnnETyTEJaJG63b5b4ccBOXr49+eCHN2U2tn2EtCABxgaQEcSrHwWjYBSMglGAGwAAe+lAQTpU6dQAAAAASUVORK5CYII=","orcid":"","institution":"Charles Sturt University","correspondingAuthor":true,"prefix":"","firstName":"Kelly","middleName":"A.","lastName":"Baker","suffix":""},{"id":444955887,"identity":"8511d973-0b9e-4cbb-b90d-cb8462441a80","order_by":1,"name":"Frank E. Marino","email":"","orcid":"","institution":"Charles Sturt University","correspondingAuthor":false,"prefix":"","firstName":"Frank","middleName":"E.","lastName":"Marino","suffix":""},{"id":444955888,"identity":"1b23a68c-6168-4292-9e5e-dd0ee457a857","order_by":2,"name":"Tegan E. Hartmann","email":"","orcid":"","institution":"Charles Sturt University","correspondingAuthor":false,"prefix":"","firstName":"Tegan","middleName":"E.","lastName":"Hartmann","suffix":""}],"badges":[],"createdAt":"2025-04-01 01:38:09","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-6348408/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-6348408/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":82079344,"identity":"430383e4-eb24-43fb-9978-2f0b677e02ea","added_by":"auto","created_at":"2025-05-06 14:12:21","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":263454,"visible":true,"origin":"","legend":"\u003cp\u003eHeart Rate and Rating of Perceived Exertion Responses\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eNote. \u003c/em\u003eMean ± \u003cem\u003eSD\u003c/em\u003e for (a) heart rate responses and (b) rating perceived exertion over the 12-week training period.\u003c/p\u003e\n\u003cp\u003e*Denotes significant difference compared to baseline (\u003cem\u003ep \u003c/em\u003e\u0026lt; .05)\u003c/p\u003e\n\u003cp\u003e^Denotes significant difference between the groups (\u003cem\u003ep \u003c/em\u003e\u0026lt; .05)\u003c/p\u003e","description":"","filename":"floatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-6348408/v1/e23707777d3e35474aa068e4.png"},{"id":82079928,"identity":"15885828-4be3-42ef-81d2-a556f9a3cb03","added_by":"auto","created_at":"2025-05-06 14:20:21","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":228582,"visible":true,"origin":"","legend":"\u003cp\u003eInflammatory Responses\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eNote. \u003c/em\u003eMean ± \u003cem\u003eSD\u003c/em\u003e for (a) CRP, (b) TNF, and (c) IL-17 pre-, mid-, and post-intervention.\u003c/p\u003e\n\u003cp\u003e*Denotes significant difference compared to baseline (\u003cem\u003ep \u003c/em\u003e\u0026lt; .05). ^Denotes significant difference between the groups (\u003cem\u003ep \u003c/em\u003e\u0026lt; .05)\u003c/p\u003e","description":"","filename":"floatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-6348408/v1/1cc6ec19fbc47e5bdae0fa24.png"},{"id":82079926,"identity":"a7c7b674-3f02-4f4a-b45f-84b43fd50d34","added_by":"auto","created_at":"2025-05-06 14:20:21","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":39368,"visible":true,"origin":"","legend":"\u003cp\u003eExercise Intervention Progression\u003c/p\u003e","description":"","filename":"floatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-6348408/v1/a8f9ab09fe26c1e2fb94d80c.png"},{"id":82684153,"identity":"c8b5119a-3117-4a61-afcc-39df11cbf9d6","added_by":"auto","created_at":"2025-05-14 06:32:06","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1675808,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6348408/v1/54cce501-8515-487a-894e-e64ec6976575.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Immune-modulating effects of regular aerobic exercise in gastrointestinal disorders: Inflammatory markers and heart rate variability","fulltext":[{"header":"Introduction","content":"\u003cp\u003eThe prevalence of gastrointestinal (GI) disorders, such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), is increasing [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. IBD is primarily comprised of Crohn\u0026rsquo;s disease (CD) and ulcerative colitis (UC) [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. This chronic idiopathic condition is characterised pathologically by intestinal inflammation which dominates the mucosa that destructs the structure and function of the GI tract [\u003cspan additionalcitationids=\"CR5\" citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. In contrast, IBS is characterised by altered bowel habits associated with abdominal discomfort or pain [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]; however, low-grade inflammation, immunological alterations, and disruption of the gut-brain axis (GBA) are suggested to have important roles in the development of symptoms [\u003cspan additionalcitationids=\"CR9 CR10\" citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eErratic symptoms, such as altered bowel movements with either straining (IBS-constipation) or urgency/diarrhoea (IBS-diarrhoea or IBD), abdominal pain, and rectal bleeding, are predominantly present through the fluctuation of active disease states, where there is heighten inflammation or intensification of symptoms [\u003cspan additionalcitationids=\"CR13 CR14\" citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. Such severe symptoms interfere with everyday activities, induce serious disability, provoke financial burden, and consequently, impact mental health and quality of life (QoL) [\u003cspan additionalcitationids=\"CR17 CR18 CR19 CR20 CR21\" citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. Despite the variety of treatment options available, with varying success [\u003cspan additionalcitationids=\"CR24 CR25 CR26 CR27 CR28\" citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e], the apparent need for an alternative and/or complementary therapeutic interventions for GI patients is acknowledged [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e, \u003cspan additionalcitationids=\"CR31\" citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e].\u003c/p\u003e \u003cp\u003ePhysical activity is an established therapeutic intervention for the prevention and treatment of a variety of chronic conditions [\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e], the beneficial effects of physical activity have recently gained interest to further assist those with GI disorders. Physical activity is considered safe and effective for patients with GI disorders [\u003cspan additionalcitationids=\"CR35 CR36 CR37\" citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e], with specific positive outcomes including improves QoL, well-being, and mental health among GI patients, as well as offers a protective role in the development of disease and advantageous effects on disease course [\u003cspan additionalcitationids=\"CR40 CR41 CR42 CR43\" citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e]. Although, the underling mechanisms coordinating these positive outcomes are unknown, such changes may be attributed to the immune and inflammatory responses of exercise [\u003cspan additionalcitationids=\"CR46 CR47\" citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eStudies that explore exercise among GI populations often rely on subjective measures of patients\u0026rsquo; well-being and disease activity without objective markers of inflammation or investigation of the GBA, particularly, the autonomic nervous system (ANS) component. Such subjective measures are important to understand patients\u0026rsquo; perception of exercise; however, greater exploration into the physiological mechanisms exercise modulates, such as immunological factors and autonomic aspects which contribute to the problematic symptomology, are essential to inform evidence-based exercise prescription within this population. Therefore, this study aims to investigate the immune-inflammatory responses and autonomic function to regular exercise in those with GI disorders. A secondary aim is to explore the symptomology and psychological impact of exercise. It is hypothesised people with GI disorders will observe a reduction in inflammatory markers with significant alterations in heart rate variability (HRV), specifically parameters that indicate a reduced sympathetic drive and increased parasympathetic stimulation. Additionally hypothesised, disease activity will remain stable with a reduction in anxiety and stress to occur.\u003c/p\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec3\"\u003e\n \u003ch2\u003eParticipant Characteristics\u003c/h2\u003e\n \u003cp\u003eTable\u0026nbsp;1 displays all anthropometric and descriptive variables. The AHC group achieved significant improvements in VO2peak from pre- to mid- (p = .021) and post-intervention (p = .031), F(2, 24) = 6.889. No other significant changes were observed for the other variables throughout either group (p \u0026gt; .05). Due to a 3.2–4.7% reduction in the AHC group systolic BP from pre-values, a significant between-group difference was observed at mid- (p = .049) and post-intervention (p = .039). While based on the 7.9% reduction in the GI group diastolic BP from pre-values to post-values, there was no significant between-group differences at post-intervention (p \u0026gt; .05). Further, the 2.5% decline in waist-to-hip ratio in the AHC group between pre- and mid-intervention resulted in a significant group difference at mid- (p = .047) and post-intervention (p = .035). Moreover, significant difference between groups were observed at pre-, mid- and post-intervention for all body composition measures, including weight, body mass index (BMI), waist and hip circumference, percentage of fat mass, lean mass, and fat mass (kg; p \u0026lt; .05). No significant between- or within-factor difference for heart rate response and RPE throughout the training period, as shown in Fig.\u0026nbsp;1.\u003c/p\u003e\n \u003cdiv\u003e\u003cimg src=\"data:image/png;base64,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\"\u003e\u003c/div\u003e\n \u003cp\u003eAll questionnaires and their respective results are present in Table\u0026nbsp;2. No significant within-groups changes were observed. WHO QoL scores were statistically significant between group across pre-, mid-, and post-intervention. Further, between-group significant differences were observed for anxiety scores pre- and mid-intervention; due to a 16% reduction in anxiety scores for the GI group from pre- to post-measure there was no significant difference post-intervention.\u003c/p\u003e\n \u003cdiv\u003e\u003cimg src=\"data:image/png;base64,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\"\u003e\u003c/div\u003e\n\u003c/div\u003e\n\u003ch3\u003eAutonomic Function\u003c/h3\u003e\n\u003cp\u003eAs displayed in Table\u0026nbsp;3, a significant between group interaction was identified in HRV measures of SD of normal-to-normal intervals (SDNN), F(1, 23) = 7.655, p = .011, root mean square of successive RR interval difference (RMSSD), F(1, 22) = 5.172, p = .033, high frequency (HF), F(1, 22) = 7.028, p = .015, and parasympathetic nervous system (PNS) index, F(1, 22) = 6.14, p = .021. Whereas significant pre- to post- differences were observed in AHC HF, F(2, 24) = 6.543, p = .007, LF, F(2, 24) = 7.284, p = .011, sympathetic nervous system (SNS) index, F(2, 24) = 4.334, p = .025, and PNS index, F(2, 24) = 4.619, p = .020, as well as GI low frequency (LF), F(2, 20) = 14.598, p = .002. No differences were observed in percentage of successive RR intervals (pNN50) or very low frequency (VLF).\u003c/p\u003e\n\u003cdiv\u003e\n \u003ctable id=\"Tab3\" border=\"1\"\u003e\n \u003ccaption language=\"En\"\u003e\n \u003cdiv\u003eTable 3\u003c/div\u003e\n \u003cdiv\u003e\n \u003cp\u003eHeart Rate Variability, Means and SD\u003c/p\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\"\u003e\u0026nbsp;\u003c/th\u003e\n \u003cth align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003ePre-intervention\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eMid-intervention\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003ePost-intervention\u003c/p\u003e\n \u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eMeasure\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eGI (\u003cem\u003en\u003c/em\u003e = 11)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eAHC (\u003cem\u003en\u003c/em\u003e = 13)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eGI (\u003cem\u003en\u003c/em\u003e = 11)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eAHC (\u003cem\u003en\u003c/em\u003e = 13)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eGI (\u003cem\u003en\u003c/em\u003e = 11)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eAHC (\u003cem\u003en\u003c/em\u003e = 13)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eSDNN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e39.57 ± 16.08\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e76.45 ± 38.66^\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e53.61 ± 26.82\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e72.92 ± 41.86\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e42.48 ± 21.51\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e69.42 ± 44.61\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eRMSSD\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e29.94 ± 16.89\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e47.28 ± 38.39\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e40.87 ± 27.80\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e57.91 ± 42.23\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e33.03 ± 20.86\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e71.50 ± 52.57^\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003epNN50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e11.48 ± 12.94\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e21.79 ± 19.27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e19.04 ± 23.54\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e26.71 ± 24.39\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e12.98 ± 16.92\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e35.86 ± 26.32\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eHF\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e23.91 ± 12.52\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e19.84 ± 15.47\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e23.39 ± 16.46\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e25.15 ± 11.83\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e20.57 ± 16.42\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e40.11 ± 19.20*^\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eLF\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e41.41 ± 10.99\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e29.81 ± 15.88\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e42.24 ± 16.49\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e39.99 ± 23.50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e65.65 ± 16.10*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e52.21 ± 18.03*\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eVLF\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e34.67 ± 15.93\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e50.32 ± 21.93\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e34.36 ± 23.98\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e36 ± 25.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e13.73 ± 9.18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e7.65 ± 8.86\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eSNS Index\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e1.2 ± 1.12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.49 ± 1.52\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.70 ± 2.05\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.32 ± 1.46\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.31 ± 1.55\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-0.47 ± 1.01*\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ePNS Index\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-0.65 ± 0.91\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-0.77 ± 1.67\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-0.18 ± 1.24\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.57 ± 1.32\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-0.55 ± 1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e1.13 ± 1.65*^\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"7\"\u003e\n \u003cp\u003e*Denotes significant difference compared to baseline (\u003cem\u003ep\u003c/em\u003e \u0026lt; .05)\u003c/p\u003e\n \u003cp\u003e^Denotes significant difference between the groups (\u003cem\u003ep\u003c/em\u003e \u0026lt; .05)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n\u003c/div\u003e\n\u003ch3\u003eInflammatory Response\u003c/h3\u003e\n\u003cp\u003eFigure 2 represents the inflammatory response of CRP, TNF, and IL-17. Between-group differences were observed at pre- and mid-intervention for CRP (p = .040; p = .003), and post-intervention for TNF (p \u0026lt; .002). Further, between mid- and post-intervention TNF values for AHC were reported as significant different, F(1, 10) = 58.549, p = .015. No significant outcomes were observed for IL-17.\u003c/p\u003e\n\u003ch3\u003eRelationship Among Variables\u003c/h3\u003e\n\u003cp\u003eSeveral associations between variables were revealed through a Pearson’s correlation coefficient analysis. Table\u0026nbsp;4 displays the main study variables across the cohort at pre-, mid-, and post-intervention. Interestingly, post-intervention TNF concentrations were negatively associated with a variety of HRV parameters: SDNN, r(18) = − .460, p = .041, RMDSS, r(18) = − .524, p = .018, HF, r(18) = − .592, p = .006, and pNN50, r(18) = − .528, p = .006.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 4\u0026nbsp;\u003c/strong\u003e\u003cem\u003ePearson Correlations for Main Study Variables\u0026nbsp;\u003c/em\u003e\u003c/p\u003e\n\u003cdiv\u003e\n \u003ctable id=\"Taba\" border=\"1\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ePre-intervention\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e1.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e2.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e3.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e4.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e5.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e6.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e7.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e8.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e9.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e10.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e11.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e12.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e1. Fat mass\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e2. VO\u003csub\u003e2 peak\u003c/sub\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-688**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e3. Depression\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.412*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .214\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e4. Anxiety\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.389\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .135\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.750**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e5. Stress\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.523**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .168\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.825**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.811**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e6. FAS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.164\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.232\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.523**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.563**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.586**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e7. WHO-QoL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .586**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.139\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .687**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .599**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .693**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .603**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e8. CRP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.617**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .550**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.565**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.499*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.582**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.332\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .414*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e9. TNF\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.344\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .233\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.140\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.143\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .045\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .099\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .373\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.199\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e10. SDNN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .460*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.547**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .250\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .233\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .251\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .048\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.217\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .307\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .102\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e11. RMDSS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .355\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.348\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .222\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .222\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .215\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .069\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.219\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .244\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .101\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.912**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e12. HF\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.114\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .148\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.006\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.006\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.038\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.038\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.030\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .106\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .207\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.166\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.482*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e13. pNN50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .280\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.275\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .233\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .233\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .140\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .084\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.242\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .300\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .144\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.803**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.942**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.602**\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eMid-intervention\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e1.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e2.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e3.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e4.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e5.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e6.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e7.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e8.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e9.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e10.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e11.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e12.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e1. Fat mass\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e2. VO\u003csub\u003e2 peak\u003c/sub\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .749**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e3. Depression\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.250\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .187\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e4. Anxiety\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.448*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .244\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.489*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e5. Stress\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.312\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .213\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.820**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.751**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e6. FAS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.188\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.001\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.817**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.342\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.677**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e7. WHO-QoL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .627**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.292\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .639**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .551**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .625**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .688**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e8. CRP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.469*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .570**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.236\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.073\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.169\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.252\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .391\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e9. TNF\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.512*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .327\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.306\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.181\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.236\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.511\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .599**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.527*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e10. SDNN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .148\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.379\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .276\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .181\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .358\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .028\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.066\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .235\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .322\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e11. RMDSS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .052\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.227\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .181\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .120\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .266\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .049\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.057\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .176\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .377\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.928**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e12. HF\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.023\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.056\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.152\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.047\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.069\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .030\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.059\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .111\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .352\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.316\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.577**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e13. pNN50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .032\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.229\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .149\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .180\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .242\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.014\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.039\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .110\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .329\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.851**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.928**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.624**\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ePost-intervention\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e1.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e2.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e3.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e4.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e5.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e6.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e7.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e8.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e9.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e10.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e11.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e12.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e1. Fat mass\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e2. VO\u003csub\u003e2 peak\u003c/sub\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .799*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e3. Depression\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.238\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .026\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e4. Anxiety\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.239\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .098\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.774**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e5. Stress\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.163\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .012\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.902**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.787**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e6. FAS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.090\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.095\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.776**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.605**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.735**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e7. WHO-QoL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .529**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.216\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .685**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .684**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .604**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .556**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e8. CRP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.310\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .339\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.317\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.351\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.173\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.229\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .381\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e9. TNF\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.218\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .238\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .002\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .039\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .036\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .061\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .201\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .041\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e10. SDNN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .163\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.230\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .163\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .227\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .051\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.161\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.160\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .137\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .460*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e11. RMDSS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .174\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.228\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .138\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .233\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-0.11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.157\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.215\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .201\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .524*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.960**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e12. HF\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .211\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.272\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .081\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .266\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.041\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.113\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.329\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .263\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .592*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.446*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.621**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e13. pNN50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .117\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.247\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .163\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .260\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.009\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.101\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.292\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .188\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e− .528*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.859**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.922**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e.736**\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"13\"\u003e\n \u003cp\u003e\u003cem\u003eNote.\u003c/em\u003e CRP, C-reactive protein: FAS, fatigue assessment questionnaire: HF, high frequency: pNN50, percentage of successive RR intervals: RMDSS, root mean square of successive RR interval differences: SDNN, standard deviation of N-N (normal-to-normal) intervals: TNF, tumor necrosis factor: VO\u003csub\u003e2 peak\u003c/sub\u003e, peak oxygen consumption: WHO-QoL, World Health Organisation Quality of Life.\u003c/p\u003e\n \u003cp\u003e*\u003cem\u003ep\u003c/em\u003e \u0026lt; .05: **\u003cem\u003ep\u003c/em\u003e \u0026lt; .01\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n\u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eThe purpose of this study was to investigate the immune-inflammatory responses of CRP, TNF, and IL-17, and evaluate autonomic function following 12-weeks of aerobic exercise training. Accordingly, the novel finding of this study revealed HRV parameters, specifically LF, significantly increased within the GI and AHC group post-intervention. Interestingly, among the AHC group significant changes that indicate a reduction in sympathetic drive and increased parasympathetic stimulation were observed post-intervention; therefore, these findings were partially consistent with the hypothesis as significant alterations occurred in HRV parameters. Although, in contrast to the research hypothesis, no significant within-group reduction in CRP, TNF, or IL-17 were observed. A non-significant reduction in CRP concentrations within the GI group resulted in no between-group differences post-intervention, whereas a decline in TNF within the AHC group resulted in between-group differences post-intervention. Additionally, a moderate negative correlation between TNF and parasympathetic HRV measures were observed. Collectively, these findings support the beneficial effects of exercise and safety for the prescription of exercise as a therapeutic intervention to assist with management. Further, due to the pathophysiology of IBD and IBS, people with those disorders may require longer periods of training to achieve similar advantageous effects to the AHC group, specifically for autonomic function and immune-inflammatory responses. A greater exploration of the underlying physiological mechanisms associated with GI disorders in response to other exercise modalities is required to draw conclusive results.\u003c/p\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eAutonomic Function to Training\u003c/h2\u003e \u003cp\u003eImmunity, inflammation, and motility of the GI tract is regulated by the ANS, specifically the interaction of the parasympathetic and sympathetic nervous systems [\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e, \u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e]. Evidence suggests autonomic dysfunctions occurs in patients with GI disorders, such as IBD and IBS [\u003cspan additionalcitationids=\"CR52\" citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e]. Accordingly, these results support this notion as SDNN, a time-domain HRV measure that reflects parasympathetic activity [\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e], is significant lower pre-intervention in the GI group compared to AHC; therefore, a reduction of SDNN indicates higher sympathetic response and reduced parasympathetic activity.\u003c/p\u003e \u003cp\u003eThe restoration of ANS is an important variable in the development and monitoring of therapeutic interventions for GI patients [\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e, \u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e]. Exercise exerts favourable effects on HRV that may improve autonomic modulation, through an increase of vagal activity and decrease sympathetic tone [\u003cspan additionalcitationids=\"CR58 CR59 CR60\" citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e]. As such, significant within-group increases were observed for LF, a frequency-domain parameter that is influenced by both sympathetic and parasympathetic activity [\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e], from pre- to post-exercise intervention among the GI and AHC group. The predominant evaluation of parasympathetic activity is further observed in the AHC cohort, as additional within-group significant changes post-intervention were revealed including an increase in HF and PNS index, and a decrease in SNS index. While our findings support the use of physical activity to induce autonomic modulation for GI and AHC cohorts, the blunted vagal tone distinguished in IBD and IBS may hinder adaptations to the ANS [\u003cspan additionalcitationids=\"CR63\" citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eInflammatory Response to Training\u003c/h3\u003e\n\u003cp\u003eRegular exercise promotes a reduction in low-grade systemic inflammation through the inhibitory effect on pro-inflammatory cytokine production derived from acute bouts of exercise [\u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e, \u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e66\u003c/span\u003e]. This is identified in a variety of studies with various clinical and non-clinical cohorts [\u003cspan additionalcitationids=\"CR68 CR69 CR70\" citationid=\"CR67\" class=\"CitationRef\"\u003e67\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR71\" class=\"CitationRef\"\u003e71\u003c/span\u003e]. Despite an observed reduction in CRP among the GI group, our findings did not achieve within-group statistical significance for either cohort. Additionally, the greater decline of TNF within the AHC group resulted in between-group significance differences post-intervention. While there is minimal evidence regarding this process among those GI patients [\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e, \u003cspan citationid=\"CR72\" class=\"CitationRef\"\u003e72\u003c/span\u003e], no notable effects may be explained with two reasons: (1) the immunological-inflammatory alterations involved in GI patients [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e] may hinder the immune-modulating effects of exercise and require a longer exercise intervention to stimulus change, and (2) due to the medication use among the GI cohort. As medication is designed to suppress intestinal inflammation [\u003cspan citationid=\"CR73\" class=\"CitationRef\"\u003e73\u003c/span\u003e], the exercise-induced immune-modulating effect may be inhibited. More specifically, the half-life of medication varies from hours to weeks depending on the medication and dose [\u003cspan additionalcitationids=\"CR75\" citationid=\"CR74\" class=\"CitationRef\"\u003e74\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR76\" class=\"CitationRef\"\u003e76\u003c/span\u003e]; therefore, the timing between medication and the exercise stimulus requires investigation to potentially elicit the advantageous immune-inflammatory adaptations. Furthermore, as no influx of pro-inflammatory markers occurred or increase in disease activity questionnaire, this study supports the safety of moderate-intensity aerobic exercise among patients with IBD and IBS.\u003c/p\u003e\n\u003ch3\u003eRelationship Amongst Autonomic Function and Inflammatory Response to Training\u003c/h3\u003e\n\u003cp\u003eDespite the minimal significant changes among HRV and inflammatory response, this study observed a significant negative correlation between TNF concentrations and a variety of parasympathetic HRV measures post-intervention. This association that indicates an increase of parasympathetic HRV parameters is related to a decrease in inflammatory TNF is anticipated, given the physiological relationship of the PNS, through the vagus nerve, and inflammatory processes [\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e]. The vagus nerve is recognised as the primary connection between local inflammation and central nervous system (CNS) activity [\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e]. More specifically, the production of pro-inflammatory cytokines, such as TNF, is modulated through vagal efferent activation of the cholinergic anti-inflammatory pathway and the afferent regulation of the HPA axis [\u003cspan additionalcitationids=\"CR78\" citationid=\"CR77\" class=\"CitationRef\"\u003e77\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR79\" class=\"CitationRef\"\u003e79\u003c/span\u003e]. In theory, activating the vagus nerve will stimulate the anti-inflammatory properties, reduce abnormal inflammation, and balance the dysregulated ANS. Although, due to limited evidence, Sadowski, Dunlap [\u003cspan citationid=\"CR80\" class=\"CitationRef\"\u003e80\u003c/span\u003e] recommends the associated HRV parameters with GI pathology remains speculative. While the underlying physiological mechanisms that influence ANS and vagus tone in people with GI disorders warrant further investigation, our findings highlight a noteworthy outcome that aerobic exercise can influence HRV parameters and further results in a decline of inflammatory markers. To strengthen these findings, exploration of exercise modalities in relation to inflammation and HRV is required.\u003c/p\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eLimitations\u003c/h2\u003e \u003cp\u003eInitially, AHC were intended to be \u0026lsquo;matched\u0026rsquo; with the GI cohort for body composition; however, as recruitment transpired, the two cohorts were not matched with several body composition measures and were identified to be significantly different between the groups. Given that pro- and anti-inflammatory factors are produced and released in adipose tissue [\u003cspan citationid=\"CR81\" class=\"CitationRef\"\u003e81\u003c/span\u003e], future research should attempt to recruitment \u0026lsquo;healthy matched controls\u0026rsquo; to regulate this variable. Additionally, participants were instructed to abstain from caffeine, alcohol, and strenuous physical activity prior to all testing session, and continue everyday life activities throughout the intervention; although, conformity was difficult to manage and entrusted with the individual. Finally, medication usage of participants was not strictly monitored during this study.\u003c/p\u003e \u003c/div\u003e"},{"header":"Conclusion","content":"\u003cp\u003eIn conclusion, the findings from the present study suggest 12-weeks of moderate intensity aerobic exercise is effective to modulate autonomic function, specifically autonomic balance, and provide a slight reduction to inflammatory cytokines that could be biologically relevant among those with GI disorders. Moreover, it is speculated that the blunted vagal tone, dysregulated inflammatory profiles, and medication use associated with GI disorders may dampen the velocity of change. These results support the use of physical activity as a therapeutic intervention, in combination with other management strategies, including medication, to maintain health, well-being and physical fitness. To further inform health professionals with favourable exercise interventions, the amelioration of ANS, activation of the vagus nerve, and mitigation of immune-inflammatory response of different exercise modalities requires investigation.\u003c/p\u003e \u003c/div\u003e "},{"header":"Methods","content":"\u003ch2\u003eParticipants\u003c/h2\u003e\n\u003cp\u003eTwenty-six participants were initially recruited, and 24 participants completed the study by participating in the 12-week exercise intervention (female: n\u0026thinsp;=\u0026thinsp;16, male: n\u0026thinsp;=\u0026thinsp;8), yielding a total drop-out rate of 8%. All participants were recruited from the general community and allocated into one of two groups: GI group (IBD, n\u0026thinsp;=\u0026thinsp;6; IBS, n\u0026thinsp;=\u0026thinsp;5; total n\u0026thinsp;=\u0026thinsp;11) or reporting as apparently healthy controls (AHC; n\u0026thinsp;=\u0026thinsp;13). All participants were between 18 and 63 years of age, Caucasian and were non-smokers. A variety of comorbid conditions were present in the GI group (depression, n\u0026thinsp;=\u0026thinsp;2; type 2 diabetes, n\u0026thinsp;=\u0026thinsp;1; fibromyalgia and chronic fatigue, n\u0026thinsp;=\u0026thinsp;1). For participants in the GI group receiving medication as treatment (n\u0026thinsp;=\u0026thinsp;5/11), a stable dose was required; however, due to the nature of disease, medication varied throughout the intervention. In total, 8 of 11 GI participants were receiving medications (specific IBD medication, n\u0026thinsp;=\u0026thinsp;5; anti-depressants, n\u0026thinsp;=\u0026thinsp;2; and thyroid medication, n\u0026thinsp;=\u0026thinsp;1). AHC had no known illness, disease, or condition, and were free from any form of cancer, diabetes, cardiovascular disease, epilepsy, multiple sclerosis, Parkinson\u0026rsquo;s disease, Alzheimer\u0026rsquo;s disease, or other neuromotor disorders, and any other diseases or conditions associated with systemic inflammatory responses. Participants were not excluded based on inflammatory biomarkers, disease activity, medication use, or physical activity behaviours.\u003c/p\u003e\n\u003ch2\u003eEthics Declaration\u003c/h2\u003e\n\u003cp\u003ePrior to commencement of the study, all participants were required to provide verbal and written consent following an outline of all procedures and measures. Informed consent was obtained from all participants. This study conformed to the Declaration of Helsinki and was approved by the Human Research Ethics Committee (protocol number: H22224), Biosafety Committee (protocol number: B22003HB), and Radiation Safety Committee (protocol number: R22003RP) at Charles Sturt University.\u003c/p\u003e\n\u003ch2\u003eStudy Overview\u003c/h2\u003e\n\u003cp\u003ePrior to enrolment, IBD participants were required to undergo medical screening by their general practitioner (GP) for confirmation of diagnosis and admittance into the study; IBS participants were screened for eligibility according to the Rome IV criteria [\u003cspan class=\"CitationRef\"\u003e82\u003c/span\u003e]. All participants had their health characteristics assessed through a health history questionnaire and an Adult Pre-Exercise Screening System (APSS). Participants then reported to the laboratory between 0500hr and 0900hr rested and fasted (10hr overnight fast) for an initial baseline testing that included a blood sample, measures of anthropometry, dual-energy x-ray absorptiometry (DEXA) scan, and a graded exercise test (GXT). Following baseline testing, all participants began the 12-week aerobic training intervention, 3 sessions/week. Additional testing sessions, comprising of the same pre-test procedures, were completed at 6-weeks (mid-intervention) and 12-weeks (post-intervention). An overview is displayed in Fig. 3.\u003c/p\u003e\n\u003ch2\u003eExercise Intervention Progression\u003c/h2\u003e\n\u003ch2\u003eTesting Sessions\u003c/h2\u003e\n\u003cp\u003eFollowing recruitment, participants attended a pre-testing session between 0500hr and 0900hr in a rested and fasted state (10hr overnight fast). All participants completed a Fatigue Assessment Questionnaire (FAS), Depression, Anxiety, and Stress Scales (DASS)-21, and the World Health Organisation Quality of Life (WHO QoL)-BREF. Additional disease-specific questionnaires were used to assess disease severity for the GI group: Harvey-Bradshaw Index (HBI), the Simple Clinical Colitis Activity Index (SCCAI), or the IBS-Symptom Severity Scale (IBS-SSS) for CD, UC, and IBS, respectively. Then a blood sample was collected (subsequently described), followed by the collection of anthropometry assessments based on standardised techniques: stature (Stadiometer: Custom CSU, Bathurst, Australia), body mass (HW 150 K, A \u0026amp; D, Bradford, MA, USA), waist and hip girths (Steel tape, EC P3 metric graduation, Sydney, NSW, Australia), resting blood pressure (BP; Welch Allyn, Arden, North Carolina, USA), heart rate (HR; Rs800cx, Vantage NV, Polar, Finland), and a 5min heart rate variability (HRV) recording (Polar Team Pro, Polar Electro Oy, Kempele, Finland). Participants then underwent a DEXA scan to determine body fat percentage, total fat mass, and lean mass (GE Lunar Prodigy, GE Healthcare, Madison, WI, USA). Lastly, participants performed a GXT on an electronically braked cycle ergometer (LODE Excalibur Sport, LODE BV, Groningen, The Netherlands) for the determination of peak oxygen consumption (VO2peak); expired gases were analysed by a calibrated metabolic cart (TrueOne 2400, ParvoMedics, Salt Lake City, Utah). The GXT increased 25 Watts (W) per minute until volitional exhaustion and commenced at either 25 W or 100 W. Every minute, rated of perceived exertion (RPE) and HR was recorded.\u003c/p\u003e\n\u003cp\u003eUpon completion of 6-weeks and 12-weeks of the intervention, all participants returned to the laboratory for mid-testing and post-testing procedures, respectively, that comprised of the same standardised pre-testing session.\u003c/p\u003e\n\u003ch2\u003eExercise Intervention\u003c/h2\u003e\n\u003cp\u003eFollowing the pre-testing session, all participants began the 12-week aerobic exercise training intervention that consisted of a continuous stationary cycle ergometry (Monark 828E, Monark Exercise AB, Varburg, Sweden). Training intensity or duration increased in 3-week blocks, as shown in Fig.\u0026nbsp;1: week 1\u0026ndash;3, 65% of heart rate reserve (HRR) for 35min; week 4\u0026ndash;6, 65% of HRR for 40min; week 7\u0026ndash;9, 70% of HRR for 40min; and week 10\u0026ndash;12, 70% of HRR for 45min (three supervised sessions per week). Every 5min RPE (Borg 0\u0026ndash;10) [\u003cspan class=\"CitationRef\"\u003e83\u003c/span\u003e] and HR (Vantage NV, Polar, Kempele, Finland) were recorded to ensure training intensity was safely adhered to. All sessions were supervised by a member of the research team with a 24-48hr recovery period interspersed between each session. Participants were instructed to continue normal lifestyle behaviour outside the parameters of the study.\u003c/p\u003e\n\u003ch2\u003eBiomarker Quantification\u003c/h2\u003e\n\u003cp\u003eVenous blood was collected to determine inflammatory markers pre-, mid- and post-intervention via a 21-gauge winged butterfly needle into the medical antecubital vein. Approximately 25ml of blood was manually drawn by syringe, ejected, and aliquoted into ethylenediaminetetraacetic acid (EDTA) tubes and a serum-separating tube (SST) for analysis of C-reactive protein (CRP), tumor necrosis factor (TNF), and interleukin (IL)-17. EDTA tubes were centrifuged immediately at 3500 rpm for 15min at 4⁰C; SST were left to clot for approximately 30min then centrifuged at 3500 rpm for 15min. Supernatants were immediately stored at -80⁰C until analysis. Samples were analysed in duplicate with a sandwich enzyme immunoassay technique (Thermo Scientific Multiskan FC), according to manufacturer\u0026rsquo;s instructions and analytical techniques: CRP at a 25 000 fold dilution (C Reactive Protein Human ELISA Kit, catalog number 1063321-1, abcam, Cambridge, United Kingdom), TNF at a 1:2 fold dilution (Human TNF alpha SimpleStep ELISA Kit, catalog number 2101050759, abcam, Cambridge, United Kingdom), and IL-17 high sensitively (HS; Human IL-17 Immunoassay, catalog number HS170). Intra-assay and inter-assay coefficients of variation were \u0026lt;\u0026thinsp;10% and \u0026lt;\u0026thinsp;12% for CRP, 2.5% and 3.1% for TNF, and 3.5% and 6.9% for IL-17HS, respectively.\u003c/p\u003e\n\u003ch2\u003eStatistical Analysis\u003c/h2\u003e\n\u003cp\u003eMean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard deviation (SD) was used to report all anthropometric, descriptive and questionnaire data. A two-way mixed analysis of variance (ANOVA; group x time) with a Bonferroni correction was applied to determine main and interaction effects. The assumption of normality was assessed by the Shapiro-Wilk W test with violations reported or log transformation applied. The assumption of homogeneity of variances was assessed by Levene\u0026rsquo;s Test of Equality of Error Variances and Box\u0026rsquo;s Test of Equality of Covariance Matrices with violations reported. Mauchly\u0026rsquo;s Test of Sphericity was applied for within-subject effects. To determine a significant difference between pre-, mid-, and post- characteristics and performance measures, a one-way repeated ANOVA was used with a one-way ANOVA used for between group differences. To determine relationships among variables, Pearson\u0026rsquo;s Correlation Coefficients were used. Significance was set at p\u0026thinsp;\u0026lt;\u0026thinsp;.05. All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS; IMB SPSS Statistics for Windows, Version 27.0. Armonk, NY). A priori power analysis was completed using G*Power (G*Power v3.1.9.6). For statistical power of 0.80, the output parameters determined a sample size of 28 was required. However, this study had a power of 0.70 with a sample size of 24. While the sample size and power are reflective of the availability of research participants in regional and rural Australia, we recognise the potential limitation of reduced power. Nevertheless, even with marginally reduced statistical power, the study provides a unique snapshot of the effects of exercise training in this group.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors would like to thank the participants for participating in this 12-week training study. The authors would like to acknowledge the Charles Sturt University open access publishing grant. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cu\u003eKelly A. Baker\u003c/u\u003e: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Resources; Validation; Writing \u0026ndash; original draft; Writing \u0026ndash; review \u0026amp; editing.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cu\u003eFrank E. Marino\u003c/u\u003e: Conceptualization; Investigation; Methodology; Supervision; Validation; Writing \u0026ndash; review \u0026amp; editing.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cu\u003eTegan E. Hartmann\u003c/u\u003e: Conceptualization; Investigation; Methodology; Supervision; Validation; Writing \u0026ndash; review \u0026amp; editing.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData availability statement\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eData can be made available upon reasonable request to the corresponding author.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting Interests Statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that no completing interests exist.\u0026nbsp;\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eAlatab, S., et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u0026ndash;2017: A systematic analysis for the Global Burden of Disease Study 2017. \u003cem\u003eThe Lancet Gastroenterology \u0026amp; Hepatology\u003c/em\u003e. \u003cstrong\u003e5\u003c/strong\u003e(1), 17-30; 10.1016/S2468-1253(19)30333-4 (2020).\u003c/li\u003e\n\u003cli\u003eBlack, C.J. and Ford, A.C. Global burden of irritable bowel syndrome: Trends, predictions and risk factors. \u003cem\u003eNature Reviews Gastroenterology \u0026amp;\u003c/em\u003e \u003cem\u003eHepatology\u003c/em\u003e, 2020. \u003cstrong\u003e17\u003c/strong\u003e(8), 473-486; 10.1038/s41575-020-0286-8 (2020).\u003c/li\u003e\n\u003cli\u003eSands, B.E. From symptom to diagnosis: Clinical distinctions among various forms of intestinal inflammation. \u003cem\u003eGastroenterology\u003c/em\u003e. \u003cstrong\u003e126\u003c/strong\u003e(6), 1518-1532; 10.1053/j.gastro.2004.02.072 (2004).\u003c/li\u003e\n\u003cli\u003eCoskun, M. Intestinal epithelium in inflammatory bowel disease. \u003cem\u003eFrontiers in Medicine\u003c/em\u003e. \u003cstrong\u003e1\u003c/strong\u003e, 24; 10.3389/fmed.2014.00024 (2014).\u003c/li\u003e\n\u003cli\u003eNeurath, M.F. Cytokines in inflammatory bowel disease. \u003cem\u003eNature Reviews Immunology\u003c/em\u003e. \u003cstrong\u003e14\u003c/strong\u003e(5), 329-342; 10.1038/nri3661 (2014).\u003c/li\u003e\n\u003cli\u003eOkamoto, R. and Watanabe, M. Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. \u003cem\u003eJournal of Gastroenterology\u003c/em\u003e. \u003cstrong\u003e51\u003c/strong\u003e(1), 11-21; 10.1007/s00535-015-1098-4 (2016).\u003c/li\u003e\n\u003cli\u003eDrossman, D.A. and Dumitrascu, D.L.Rome III: New standard for functional gastrointestinal disorders. \u003cem\u003eJournal of Gastrointestinal and Liver Diseases: JGLD\u003c/em\u003e. \u003cstrong\u003e15\u003c/strong\u003e(3), 237-241; (2006).\u003c/li\u003e\n\u003cli\u003eFichna, J. and Storr, M.A. Brain-gut interactions in IBS. \u003cem\u003eFrontiers in Pharmacology\u003c/em\u003e. \u003cstrong\u003e3\u003c/strong\u003e, 127; 10.3389/fphar.2012.00127 (2012).\u003c/li\u003e\n\u003cli\u003eNg, Q.X., Soh, A.Y.S., Loke,W., Lim, D.Y., \u0026amp; Yeo, W.S. The role of inflammation in irritable bowel syndrome (IBS). \u003cem\u003eJournal of Inflammation Research\u003c/em\u003e. 345-349; 10.2147/JIR.S174982 (2018).\u003c/li\u003e\n\u003cli\u003e\u0026Ouml;hman, L. and Simr\u0026eacute;n, M. Pathogenesis of IBS: Role of inflammation, immunity and neuroimmune interactions. \u003cem\u003eNature Reviews Gastroenterology \u0026amp; Hepatology\u003c/em\u003e. \u003cstrong\u003e7\u003c/strong\u003e(3), 163-173; 10.1038/nrgastro.2010.4 (2010).\u003c/li\u003e\n\u003cli\u003eVidelock, E.J. and Chang, L. Latest insights on the pathogenesis of irritable bowel syndrome. \u003cem\u003eGastroenterology Clinics\u003c/em\u003e. \u003cstrong\u003e50\u003c/strong\u003e(3), 505-522; 10.1016/j.gtc.2021.04.002 (2021).\u003c/li\u003e\n\u003cli\u003ePerler, B.K., et al., Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort. \u003cem\u003eBMC Gastroenterology\u003c/em\u003e. \u003cstrong\u003e19\u003c/strong\u003e(1), 1-8; 10.1186/s12876-019-0963-7 (2019).\u003c/li\u003e\n\u003cli\u003ePeyrin-Biroulet, L., Loftus, E.V., Colombel, J.F., \u0026amp; Sandborn, W.J. Defining disease severity in inflammatory bowel diseases: Current and future directions. \u003cem\u003eClinical Gastroenterology and Hepatology\u003c/em\u003e. \u003cstrong\u003e14\u003c/strong\u003e(3), 348-354, e17; 10.1002/ibd.21417 (2016).\u003c/li\u003e\n\u003cli\u003eShah, E.D., Almario, C.V., Spiegel, B.M., \u0026amp; Chey, W.D. Presentation and characteristics of abdominal pain vary by irritable bowel syndrome subtype: Results of a nationwide population-based study. \u003cem\u003eThe American Journal of Gastroenterology\u003c/em\u003e. \u003cstrong\u003e115\u003c/strong\u003e(2), 294; 10.14309/ajg.0000000000000502 (2020).\u003c/li\u003e\n\u003cli\u003eSoares, R.L., Irritable bowel syndrome: A clinical review. \u003cem\u003eWorld Journal of Gastroenterology: WJG\u003c/em\u003e. \u003cstrong\u003e20\u003c/strong\u003e(34), 12144-12160; 10.3748%2Fwjg.v20.i34.12144 (2014).\u003c/li\u003e\n\u003cli\u003eBarberio, B., Zamani, M., Black, C.J., Savarino, E.V., \u0026amp; Ford, A.C. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: A systematic review and meta-analysis. \u003cem\u003eThe Lancet Gastroenterology \u0026amp; Hepatology\u003c/em\u003e. \u003cstrong\u003e6\u003c/strong\u003e(5), 359-370; 10.1016/S2468-1253(21)00014-5 (2021).\u003c/li\u003e\n\u003cli\u003eH\u0026auml;user, W., Layer, P., Henningsen, P., \u0026amp; Kruis, W. Functional bowel disorders in adults. \u003cem\u003eDeutsches \u0026Auml;rzteblatt International\u003c/em\u003e. \u003cstrong\u003e109\u003c/strong\u003e(5), 83; 10.3238%2Farztebl.2012.0083 (2012).\u003c/li\u003e\n\u003cli\u003eJones, J.L., et al. The impact of inflammatory bowel disease in Canada 2018: Quality of life. \u003cem\u003eJournal of the Canadian Association of Gastroenterology\u003c/em\u003e. \u003cstrong\u003e2\u003c/strong\u003e(Supplement_1), S42-S48; 10.1093/jcag/gwy048 (2019).\u003c/li\u003e\n\u003cli\u003eLiang, A.M. and Y. Tien, Quality of life in irritable bowel syndrome: A narrative overview. \u003cem\u003eJournal of Archives in Military Medicine\u003c/em\u003e. \u003cstrong\u003e4\u003c/strong\u003e(1); 10.5812/jamm.36624 (2016).\u003c/li\u003e\n\u003cli\u003eMikocka‐Walus, A., et al. Psychological comorbidity and complexity of gastrointestinal symptoms in clinically diagnosed irritable bowel syndrome patients. \u003cem\u003eJournal of Gastroenterology and Hepatology\u003c/em\u003e. \u003cstrong\u003e23\u003c/strong\u003e(7pt1), 1137-1143; 10.1111/j.1440-1746.2007.05245.x (2008).\u003c/li\u003e\n\u003cli\u003eZamani, M., Alizadeh‐Tabari, S. and Zamani, V. Systematic review with meta‐analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. \u003cem\u003eAlimentary Pharmacology \u0026amp; Therapeutics\u003c/em\u003e. \u003cstrong\u003e50\u003c/strong\u003e(2), 132-143; 10.1111/apt.15325 (2019).\u003c/li\u003e\n\u003cli\u003eBaker, K.A., Marino, F.E. and Hartmann, T.E. Living with inflammatory bowel disease in Australia: Quality of life and the impact of support networks. \u003cem\u003eTherapeutic Advances in Gastroenterology\u003c/em\u003e. \u003cstrong\u003e17\u003c/strong\u003e; 10.1177/17562848241264362 (2024).\u003c/li\u003e\n\u003cli\u003eBertani, L., et al. Fecal calprotectin predicts mucosal healing in patients with ulcerative colitis treated with biological therapies: A prospective study. \u003cem\u003eClinical and Translational Gastroenterology\u003c/em\u003e. \u003cstrong\u003e11\u003c/strong\u003e(5); 10.14309/ctg.0000000000000174 (2020).\u003c/li\u003e\n\u003cli\u003eChudy-Onwugaje, K.O., Christian, K. E. Farraye, F. A. \u0026amp; Cross, R. K. A state-of-the-art review of new and emerging therapies for the treatment of IBD. \u003cem\u003eInflammatory Bowel Diseases\u003c/em\u003e. \u003cstrong\u003e25\u003c/strong\u003e(5), 820-830; 10.1093/ibd/izy327 (2019).\u003c/li\u003e\n\u003cli\u003eDuff, W., et al. Non-pharmacological therapies for inflammatory bowel disease: Recommendations for self-care and physician guidance. \u003cem\u003eWorld Journal of Gastroenterology\u003c/em\u003e. \u003cstrong\u003e24\u003c/strong\u003e(28), 3055-3070; 10.3748%2Fwjg.v24.i28.3055 (2018).\u003c/li\u003e\n\u003cli\u003eIm, J.P., et al. Changing treatment paradigms for the management of inflammatory bowel disease. \u003cem\u003eThe Korean Journal of Internal Medicine\u003c/em\u003e. \u003cstrong\u003e33\u003c/strong\u003e(1), 28; 10.3904%2Fkjim.2017.400 (2018).\u003c/li\u003e\n\u003cli\u003eKo, Y. and Ho, V. Irritable bowel syndrome an update on diagnosis and management. \u003cem\u003eMedicine Today\u003c/em\u003e. \u003cstrong\u003e22\u003c/strong\u003e(8); (2021).\u003c/li\u003e\n\u003cli\u003eShorey, S., Demutska, A. Chan, V. \u0026amp; Siah, K.T.H. Adults living with irritable bowel syndrome (IBS): A qualitative systematic review. \u003cem\u003eJournal of Psychosomatic Research\u003c/em\u003e. \u003cstrong\u003e140\u003c/strong\u003e, 110289; 10.1016/j.jpsychores.2020.110289 (2021).\u003c/li\u003e\n\u003cli\u003evan Linschoten, R.C.A., et al. Systematic review: Societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. \u003cem\u003eAlimentary Pharmacology \u0026amp; Therapeutics\u003c/em\u003e. \u003cstrong\u003e54\u003c/strong\u003e(3), 234-248; 10.1111/apt.16445 (2021).\u003c/li\u003e\n\u003cli\u003eAmsallem, F., Sanchez, S. Armoiry, X. \u0026amp; Mion, F. Effectiveness of non-pharmacological interventions for irritable bowel syndrome: A systematic review. \u003cem\u003eEvidence-Based Complementary and Alternative Medicine\u003c/em\u003e. \u003cstrong\u003e2021\u003c/strong\u003e(1); 10.1155/2021/4404185 (2021).\u003c/li\u003e\n\u003cli\u003eBilski, J., et al. Can exercise affect the course of inflammatory bowel disease? Experimental and clinical evidence. \u003cem\u003ePharmacological Reports\u003c/em\u003e. \u003cstrong\u003e68\u003c/strong\u003e(4), 827-836; 10.1016/j.pharep.2016.04.009 (2016).\u003c/li\u003e\n\u003cli\u003eYoon, S.L., Grundmann, O. Koepp, L. \u0026amp; Farrell, L. Management of irritable bowel syndrome (IBS) in adults: Conventional and complementary/alternative approaches. \u003cem\u003eAlternative Medicine Review\u003c/em\u003e. \u003cstrong\u003e16\u003c/strong\u003e(2), 134-151; (2011).\u003c/li\u003e\n\u003cli\u003eThompson, W.R., et al. Exercise is medicine. \u003cem\u003eAmerican Journal of Lifestyle Medicine\u003c/em\u003e. \u003cstrong\u003e14\u003c/strong\u003e(5), 511-523; 10.1177/1559827620912192 (2020).\u003c/li\u003e\n\u003cli\u003eBaker, K.A., Miller, T.D. Marino, F.E. \u0026amp; Hartmann, T.E. The exercise-induced inflammatory response in inflammatory bowel disease: A systematic review and meta-analysis. \u003cem\u003ePloS One\u003c/em\u003e. \u003cstrong\u003e17\u003c/strong\u003e(2), e0262534; 10.1371/journal.pone.0262534 (2022).\u003c/li\u003e\n\u003cli\u003eCronin, O., et al., Moderate-intensity aerobic and resistance exercise is safe and favorably influences body composition in patients with quiescent Inflammatory Bowel Disease: A randomized controlled cross-over trial. \u003cem\u003eBMC Gastroenterology\u003c/em\u003e. \u003cstrong\u003e19\u003c/strong\u003e(1), 1-11; 10.1186/s12876-019-0952-x (2019).\u003c/li\u003e\n\u003cli\u003eKlare, P., et al. The impact of a ten-week physical exercise program on health-related quality of life in patients with inflammatory bowel disease: A prospective randomized controlled trial. \u003cem\u003eDigestion\u003c/em\u003e. \u003cstrong\u003e91\u003c/strong\u003e(3), 239-247; 10.1159/000371795 (2015).\u003c/li\u003e\n\u003cli\u003eRadziszewska, M., Smarkusz-Zarzecka, J. and Ostrowska, L. Nutrition, physical activity and supplementation in irritable bowel syndrome. \u003cem\u003eNutrients\u003c/em\u003e. \u003cstrong\u003e15\u003c/strong\u003e(16); 10.3390/nu15163662 (2023).\u003c/li\u003e\n\u003cli\u003eRey, E., The role of physical exercise in the treatment of IBS. \u003cem\u003eNeuro Gastro Latem Reviews\u003c/em\u003e, \u003cstrong\u003e3\u003c/strong\u003e(2), 92-104; 10.24875/NGL.19000033 (2019).\u003c/li\u003e\n\u003cli\u003eDavis, S.P., Crane, P.B. Bolin, L.P. \u0026amp; Johnson, L.A. An integrative review of physical activity in adults with inflammatory bowel disease. \u003cem\u003eIntestinal Research\u003c/em\u003e. \u003cstrong\u003e20\u003c/strong\u003e(1), 43-52; 10.5217/ir.2020.00049 (2021).\u003c/li\u003e\n\u003cli\u003eGao, X., Tian, S. Huang, N. Sun, G. \u0026amp; Huang, T. Associations of daily sedentary behavior, physical activity, and sleep with irritable bowel syndrome: A prospective analysis of 362, 193 participants. \u003cem\u003eJournal of Sport and Health Science\u003c/em\u003e. 10.1016/j.jshs.2023.02.002 (2023).\u003c/li\u003e\n\u003cli\u003eHolik, D., et al. The effect of daily physical activity on the activity of inflammatory bowel diseases in therapy-free patients. \u003cem\u003eActa Clinica Croatica\u003c/em\u003e. \u003cstrong\u003e58\u003c/strong\u003e(2), 202-211; 10.20471/acc.2019.58.02.02 (2019).\u003c/li\u003e\n\u003cli\u003eJohannesson, E., Ringstr\u0026ouml;m, G. Abrahamsson, H. \u0026amp; Sadik, R. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. \u003cem\u003eWorld Journal of Gastroenterology: WJG\u003c/em\u003e. \u003cstrong\u003e21\u003c/strong\u003e(2), 600-608; 10.3748%2Fwjg.v21.i2.600 (2015).\u003c/li\u003e\n\u003cli\u003eLamers, C.R., de Roos, N.M. Koppelman, L.J. Hopman, M.T. \u0026amp; Witteman, B. J. Patient experiences with the role of physical activity in inflammatory bowel disease: Results from a survey and interviews. \u003cem\u003eBMC Gastroenterology\u003c/em\u003e. \u003cstrong\u003e21\u003c/strong\u003e(1), 1-9; 10.1186/s12876-021-01739-z (2021).\u003c/li\u003e\n\u003cli\u003eMadva, E.N., et al. Positive psychological well‐being: A novel concept for improving symptoms, quality of life, and health behaviors in irritable bowel syndrome. \u003cem\u003eNeurogastroenterology \u0026amp; Motility\u003c/em\u003e. \u003cstrong\u003e35\u003c/strong\u003e(4), e14531; 10.1111/nmo.14531 (2023).\u003c/li\u003e\n\u003cli\u003eBruunsgaard, H. Physical activity and modulation of systemic low‐level inflammation. \u003cem\u003eJournal of Leukocyte Biology\u003c/em\u003e. \u003cstrong\u003e78\u003c/strong\u003e(4), 819-835; 10.1189/jlb.0505247 (2005).\u003c/li\u003e\n\u003cli\u003eMoldoveanu, A.I., Shephard, R.J. and Shek, P.N. The cytokine response to physical activity and training. \u003cem\u003eSports Medicine\u003c/em\u003e. \u003cstrong\u003e31\u003c/strong\u003e(2), 115-144; 10.2165/00007256-200131020-00004 (2001).\u003c/li\u003e\n\u003cli\u003eOrtega, E. The \u0026ldquo;bioregulatory effect of exercise\u0026rdquo; on the innate/inflammatory responses. \u003cem\u003eJournal of Physiology and Biochemistry\u003c/em\u003e. \u003cstrong\u003e72\u003c/strong\u003e(2), 361-369; 10.1007/s13105-016-0478-4 (2016).\u003c/li\u003e\n\u003cli\u003eZaldivar, F., et al. Constitutive pro-and anti-inflammatory cytokine and growth factor response to exercise in leukocytes. \u003cem\u003eJournal of Applied Physiology\u003c/em\u003e. \u003cstrong\u003e100\u003c/strong\u003e(4), 1124-1133; 10.1152/japplphysiol.00562.2005 (2006).\u003c/li\u003e\n\u003cli\u003eKim, K.-N., Yao, Y. and Ju, S.-Y. Heart rate variability and inflammatory bowel disease in humans: A systematic review and meta-analysis. \u003cem\u003eMedicine\u003c/em\u003e. \u003cstrong\u003e99\u003c/strong\u003e(48). 10.1097/MD.0000000000023430 (2020).\u003c/li\u003e\n\u003cli\u003eWilliams, D.P., et al. Heart rate variability and inflammation: A meta-analysis of human studies. \u003cem\u003eBrain, Behavior, and Immunity\u003c/em\u003e. \u003cstrong\u003e80\u003c/strong\u003e, 219-226; 10.1016/j.bbi.2019.03.009 (2019).\u003c/li\u003e\n\u003cli\u003eEngel, T., Ben-Horin, S. and Beer-Gabel, M. Autonomic dysfunction correlates with clinical and inflammatory activity in patients with Crohn\u0026apos;s disease. \u003cem\u003eInflammatory Bowel Diseases\u003c/em\u003e. \u003cstrong\u003e21\u003c/strong\u003e(10), 2320-2326; 10.1097/MIB.0000000000000508 (2015).\u003c/li\u003e\n\u003cli\u003eSharma, P., Makharia, G.K. Ahuja, V. Dwivedi, S.N. \u0026amp; Deepak, K.K. Autonomic dysfunctions in patients with inflammatory bowel disease in clinical remission. \u003cem\u003eDigestive Diseases and Sciences\u003c/em\u003e. \u003cstrong\u003e54\u003c/strong\u003e, 853-861; 10.1007/s10620-008-0424-6 (2009).\u003c/li\u003e\n\u003cli\u003eYildirim, A., et al. Is there any association between irritable bowel syndrome subgroups and autonomous dysfunction. \u003cem\u003eEuropean Review for Medical \u0026amp; Pharmacological Sciences\u003c/em\u003e. \u003cstrong\u003e20\u003c/strong\u003e(7); (2016).\u003c/li\u003e\n\u003cli\u003eAli, M.K. and Chen, J.D. Roles of Heart Rate Variability in Assessing Autonomic Nervous System in Functional Gastrointestinal Disorders: A Systematic Review. \u003cem\u003eDiagnostics\u003c/em\u003e. \u003cstrong\u003e13\u003c/strong\u003e(2), 293; 10.3390/diagnostics13020293 (2023).\u003c/li\u003e\n\u003cli\u003eMogilevski, T., Burgell, R. Aziz, Q. \u0026amp; Gibson, P.R. the role of the autonomic nervous system in the pathogenesis and therapy of IBD. \u003cem\u003eAlimentary Pharmacology \u0026amp; Therapeutics\u003c/em\u003e, 2019. \u003cstrong\u003e50\u003c/strong\u003e(7), 720-737; 10.1111/apt.15433 (2019).\u003c/li\u003e\n\u003cli\u003eSalvioli, B., et al. Autonomic nervous system dysregulation in irritable bowel syndrome. \u003cem\u003eNeurogastroenterology \u0026amp; Motility\u003c/em\u003e. \u003cstrong\u003e27\u003c/strong\u003e(3), 423-430; 10.1111/nmo.12512 (2015).\u003c/li\u003e\n\u003cli\u003eAmano, M., Kanda, T. Ue, H. \u0026amp; Moritani, T. Exercise training and autonomic nervous system activity in obese individuals. \u003cem\u003eMedicine \u0026amp; Science in Sports \u0026amp; Exercise\u003c/em\u003e. \u003cstrong\u003e33\u003c/strong\u003e(8), 1287-1291; (2001).\u003c/li\u003e\n\u003cli\u003eCollins, B.E., et al. Moderate continuous-and high-intensity interval training elicit comparable cardiovascular effect among middle-aged men regardless of recovery mode. \u003cem\u003eEuropean Journal of Sport Science\u003c/em\u003e. \u003cstrong\u003e23\u003c/strong\u003e(8),1-10; (2023).\u003c/li\u003e\n\u003cli\u003eNagai, N., Hamada, T. Kimura, T. \u0026amp; Moritani, T. Moderate physical exercise increases cardiac autonomic nervous system activity in children with low heart rate variability. \u003cem\u003eChild\u0026apos;s Nervous System\u003c/em\u003e. \u003cstrong\u003e20\u003c/strong\u003e, 209-214; 10.1007/s00381-004-0915-5 (2004).\u003c/li\u003e\n\u003cli\u003ePicard, M., et al. Effect of exercise training on heart rate variability in type 2 diabetes mellitus patients: A systematic review and meta-analysis. \u003cem\u003ePLoS One\u003c/em\u003e, 2021. \u003cstrong\u003e16\u003c/strong\u003e(5), e0251863; 10.1371/journal.pone.0251863 (2021).\u003c/li\u003e\n\u003cli\u003eRoutledge, F.S., Campbell, T.S. McFetridge-Durdle, J.A. \u0026amp; Bacon, S.L. Improvements in heart rate variability with exercise therapy. \u003cem\u003eCanadian Journal of Cardiology\u003c/em\u003e. \u003cstrong\u003e26\u003c/strong\u003e(6), 303-312; 10.1016/S0828-282X(10)70395-0 (2010).\u003c/li\u003e\n\u003cli\u003eBonaz, B., Sinniger, V. and Pellissier, S. The vagus nerve in the neuro-immune axis: implications in the pathology of the gastrointestinal tract. \u003cem\u003eFrontiers in Immunology\u003c/em\u003e. \u003cstrong\u003e8\u003c/strong\u003e, 1452; 10.3389/fimmu.2017.01452 (2017).\u003c/li\u003e\n\u003cli\u003eBonaz, B.L. and Bernstein, C.N. Brain-gut interactions in inflammatory bowel disease. \u003cem\u003eGastroenterology\u003c/em\u003e. \u003cstrong\u003e144\u003c/strong\u003e(1), 36-49; 10.1053/j.gastro.2012.10.003 (2013).\u003c/li\u003e\n\u003cli\u003ePellissier, S., Dantzer, C. Canini, F. Mathieu, N. \u0026amp; Bonaz, B. Psychological adjustment and autonomic disturbances in inflammatory bowel diseases and irritable bowel syndrome. \u003cem\u003ePsychoneuroendocrinology\u003c/em\u003e. \u003cstrong\u003e35\u003c/strong\u003e(5), 653-662. 10.1016/j.psyneuen.2009.10.004 (2010).\u003c/li\u003e\n\u003cli\u003eBeavers, K.M., Brinkley, T.E. and Nicklas, B.J. Effect of exercise training on chronic inflammation. \u003cem\u003eClinica Chimica Acta\u003c/em\u003e. \u003cstrong\u003e411\u003c/strong\u003e(11-12), 785-793. 10.1016/j.cca.2010.02.069 (2010).\u003c/li\u003e\n\u003cli\u003ePetersen, A. and Pedersen, B. The role of IL-6 in mediating the anti inflammatory. \u003cem\u003eJ Physiol Pharmacol\u003c/em\u003e. \u003cstrong\u003e57\u003c/strong\u003e(Suppl 10), 43-51; (2006).\u003c/li\u003e\n\u003cli\u003eAmbarish, V., Chandrashekara, S. and Suresh, K. Moderate regular exercises reduce inflammatory response for physical stress. \u003cem\u003eIndian J Physiol Pharmacol\u003c/em\u003e. \u003cstrong\u003e56\u003c/strong\u003e(1), 7-14; (2012).\u003c/li\u003e\n\u003cli\u003eCampbell, P.T., et al. A yearlong exercise intervention decreases CRP among obese postmenopausal women. \u003cem\u003eMedicine and Science in Sports and Exercise\u003c/em\u003e. \u003cstrong\u003e41\u003c/strong\u003e(8); 10.1249%2FMSS.0b013e31819c7feb (2009).\u003c/li\u003e\n\u003cli\u003eGoldhammer, E., et al. Exercise training modulates cytokines activity in coronary heart disease patients. \u003cem\u003eInternational Journal of Cardiology\u003c/em\u003e. \u003cstrong\u003e100\u003c/strong\u003e(1), 93-99; 10.1016/j.ijcard.2004.08.073 (2005).\u003c/li\u003e\n\u003cli\u003eMetsios, G.S., Moe, R.H. and Kitas, G.D. Exercise and inflammation\u003cem\u003e. Best Practice \u0026amp; Research Clinical Rheumatology\u003c/em\u003e. \u003cstrong\u003e32\u003c/strong\u003e(2), 101504; 10.1016/j.berh.2020.101504 (2020).\u003c/li\u003e\n\u003cli\u003eStewart, L.K., et al. The influence of exercise training on inflammatory cytokines and C-reactive protein. \u003cem\u003eMedicine and Science in Sports and Exercise\u003c/em\u003e. \u003cstrong\u003e39\u003c/strong\u003e(10), 1714; 10.1249/mss.0b013e31811ece1c (2007). \u003c/li\u003e\n\u003cli\u003eAhmad, M.N. and Thnaibat, O.M. Can physical exercise help people with irritable bowel syndrome? How substantial is the evidence? \u003cem\u003eHealth, Sport, Rehabilitation\u003c/em\u003e. \u003cstrong\u003e9\u003c/strong\u003e(4), 94-110; 10.58962/HSR.2023.9.4.94-110 (2023).\u003c/li\u003e\n\u003cli\u003eNeurath, M.F. Current and emerging therapeutic targets for IBD. \u003cem\u003eNature Reviews Gastroenterology \u0026amp; Hepatology\u003c/em\u003e. \u003cstrong\u003e14\u003c/strong\u003e(5), 269-278; 10.1038/nrgastro.2016.208 (2017).\u003c/li\u003e\n\u003cli\u003eMoreno, L.O., Fern\u0026aacute;ndez-Tom\u0026eacute;, S. and Abalo, R. Biological treatments in inflammatory bowel disease: a complex mix of mechanisms and actions. \u003cem\u003eBiologics\u003c/em\u003e. \u003cstrong\u003e1\u003c/strong\u003e(2), 189-210; 10.3390/biologics1020012 (2021).\u003c/li\u003e\n\u003cli\u003ePapamichael, K., et al. Infliximab in inflammatory bowel disease. \u003cem\u003eTherapeutic Advances in Chronic Disease\u003c/em\u003e. \u003cstrong\u003e10\u003c/strong\u003e, 2040622319838443; 10.1177/2040622319838443 (2019).\u003c/li\u003e\n\u003cli\u003eWiersma, H., et al. Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease. \u003cem\u003eInflammatory Bowel Diseases\u003c/em\u003e. \u003cstrong\u003e10\u003c/strong\u003e(5), 626-631; 10.1053/j.gastro.2018.02.014 (2004).\u003c/li\u003e\n\u003cli\u003eBonaz, B., Sinniger, V. and Pellissier, S. Anti‐inflammatory properties of the vagus nerve: potential therapeutic implications of vagus nerve stimulation. \u003cem\u003eThe Journal of Physiology\u003c/em\u003e. \u003cstrong\u003e594\u003c/strong\u003e(20), 5781-5790; 10.1113/JP271539 (2016).\u003c/li\u003e\n\u003cli\u003ePavlov, V.A., et al. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. \u003cem\u003eBrain, Behavior, and Immunity\u003c/em\u003e. \u003cstrong\u003e23\u003c/strong\u003e(1), 41-45; 10.1016/j.bbi.2008.06.011 (2009).\u003c/li\u003e\n\u003cli\u003ePellissier, S., et al. Relationship between vagal tone, cortisol, TNF-alpha, epinephrine and negative affects in Crohn\u0026rsquo;s disease and irritable bowel syndrome. \u003cem\u003ePloS One\u003c/em\u003e. \u003cstrong\u003e9\u003c/strong\u003e(9), e105328; 10.1371/journal.pone.0105328 (2014).\u003c/li\u003e\n\u003cli\u003eSadowski, A., Dunlap, C. Lacombe, A. \u0026amp; Hanes, D. Alterations in heart rate variability associated with irritable bowel syndrome or inflammatory bowel disease: A systematic review and meta-analysis. \u003cem\u003eClinical and Translational Gastroenterology\u003c/em\u003e. \u003cstrong\u003e12\u003c/strong\u003e(1); 10.14309/ctg.0000000000000275 (2021).\u003c/li\u003e\n\u003cli\u003eFantuzzi, G. Adipose tissue, adipokines, and inflammation. \u003cem\u003eJournal of Allergy and Clinical Immunology\u003c/em\u003e. \u003cstrong\u003e115\u003c/strong\u003e(5), 911-919; 10.1016/j.jaci.2005.02.023 (2005).\u003c/li\u003e\n\u003cli\u003eDrossman, D.A. and Tack, J. Rome Foundation clinical diagnostic criteria for disorders of gut-brain interaction. \u003cem\u003eGastroenterology\u003c/em\u003e, 2022. \u003cstrong\u003e162\u003c/strong\u003e(3), 675-679; 10.1053/j.gastro.2021.11.019 (2022).\u003c/li\u003e\n\u003cli\u003eBorg, G. Borg\u0026apos;s perceived exertion and pain scales. (Human kinetics, 1998).\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Inflammatory bowel disease, irritable bowel syndrome, physical activity, exercise, autonomic regulation, inflammatory response","lastPublishedDoi":"10.21203/rs.3.rs-6348408/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-6348408/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eThis study investigates the effects of a 12-week moderate-intensity aerobic exercise intervention on autonomic function, inflammatory markers, and symptom severity in those with gastrointestinal (GI) disorders, specifically inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), compared to apparently health controls (AHC). Heart rate variability (HRV) parameters, specifically low frequency, significant increased within the GI and AHC cohort post-intervention; additional increased parasympathetic parameters were observed in AHC. No significant reductions occurred in the inflammatory markers of CRP, TNF, or IL-17; although, a greater reduction in TNF concentration among AHC group resulted in a significant between-group difference post-intervention. Significant correlations indicated a negative correlation between TNF and parasympathetic HRV measures post-intervention. Twelve-weeks moderate-intensity aerobic exercise is effective to modulate autonomic function, particularly the autonomic balance, and provide a slight reduction in inflammatory cytokines among patients with GI disorders. The blunted vagal tone and dysregulated immunological-inflammatory profiles are speculated to hinder the physiological changes in IBD and IBS; although further research is required to support or refute this concept. This study supports use of exercise as a complementary intervention to maintain health, well-being, and physical fitness, without disease exacerbation or adverse effects of medication.\u003c/p\u003e","manuscriptTitle":"Immune-modulating effects of regular aerobic exercise in gastrointestinal disorders: Inflammatory markers and heart rate variability","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-05-06 14:12:16","doi":"10.21203/rs.3.rs-6348408/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"9eb08e40-ed85-4339-a134-8b7cac21d0ab","owner":[],"postedDate":"May 6th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":47377163,"name":"Biological sciences/Immunology/Inflammation/Chronic inflammation"},{"id":47377164,"name":"Health sciences/Diseases/Gastrointestinal diseases"},{"id":47377165,"name":"Health sciences/Health care/Therapeutics"}],"tags":[],"updatedAt":"2025-05-14T06:23:54+00:00","versionOfRecord":[],"versionCreatedAt":"2025-05-06 14:12:16","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-6348408","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-6348408","identity":"rs-6348408","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}